<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003418.pub2" GROUP_ID="ENDOC" ID="279600032409253179" MERGED_FROM="" MODIFIED="2008-10-28 13:41:22 +0100" MODIFIED_BY="Gudrun Paletta" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2008-10-28 13:41:22 +0100" MODIFIED_BY="Gudrun Paletta">
<TITLE>Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus</TITLE>
<CONTACT MODIFIED="2008-10-28 13:41:22 +0100" MODIFIED_BY="Gudrun Paletta"><PERSON ID="14677" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Alex</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Goudswaard</LAST_NAME><EMAIL_1>Goudswaard@nhg.org</EMAIL_1><EMAIL_2>lex@goudswaard.cx</EMAIL_2><ADDRESS><DEPARTMENT>Head of the Department of Guideline development and Research</DEPARTMENT><ORGANISATION>Dutch College of General Practitioners</ORGANISATION><ADDRESS_1>PO Box 3231</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3502 GE</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+ 31 30 2823500</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-10-28 13:41:22 +0100" MODIFIED_BY="Gudrun Paletta"><PERSON ID="14677" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Alex</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Goudswaard</LAST_NAME><EMAIL_1>Goudswaard@nhg.org</EMAIL_1><EMAIL_2>lex@goudswaard.cx</EMAIL_2><ADDRESS><DEPARTMENT>Head of the Department of Guideline development and Research</DEPARTMENT><ORGANISATION>Dutch College of General Practitioners</ORGANISATION><ADDRESS_1>PO Box 3231</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3502 GE</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+ 31 30 2823500</PHONE_1></ADDRESS></PERSON><PERSON ID="19627" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Niall</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Furlong</LAST_NAME><SUFFIX>MB, ChB, MRCP (UK)</SUFFIX><POSITION>Specialist Registrar Diabetes &amp; Endocrinology</POSITION><EMAIL_1>niallfurlong@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Diabetes and Endocrinology</DEPARTMENT><ORGANISATION>Whiston Hospital</ORGANISATION><ADDRESS_1>St Helens and Knowsley Hospitals NHS Trust</ADDRESS_1><ADDRESS_2>Warrington Road</ADDRESS_2><CITY>Prescot</CITY><ZIP>L35 5DR</ZIP><REGION>Merseyside</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 430 1912</PHONE_1><FAX_1>+44 151 430 1900</FAX_1></ADDRESS></PERSON><PERSON ID="8865" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gerlof</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>Valk</LAST_NAME><POSITION>Senior Researcher</POSITION><EMAIL_1>g.valk@xs4all.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>University Medical Centre Utrecht</ORGANISATION><ADDRESS_1>P.O.Box 85500</ADDRESS_1><CITY>3508 GA Utrecht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 4448199</PHONE_1><FAX_1>+31 20 4448361</FAX_1></ADDRESS></PERSON><PERSON ID="19654" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ronald </FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Stolk</LAST_NAME><EMAIL_1>r.p.stolk@epi.umcg.nl </EMAIL_1><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>University Medical Center Groningen</ORGANISATION><CITY>Groningen</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="14739" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Guy</FIRST_NAME><MIDDLE_INITIALS>EHM</MIDDLE_INITIALS><LAST_NAME>Rutten</LAST_NAME><POSITION>Professor and GP</POSITION><EMAIL_1>g.e.h.m.rutten@med.uu.nl</EMAIL_1><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>Postbus 85500, Str. 6.131</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 30 2538154</PHONE_1><FAX_1>+31 30 2539028</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-28 13:07:08 +0100" MODIFIED_BY="Gudrun Paletta">
<UP_TO_DATE>
<DATE DAY="30" MONTH="5" YEAR="2004"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="5" YEAR="2004"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="5" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2004"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="3" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-03 16:50:14 +0200" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Julius Center for Health Science and Primary Care</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-28 13:39:25 +0100" MODIFIED_BY="Gudrun Paletta">
<SUMMARY MODIFIED="2008-10-19 16:43:05 +0200" MODIFIED_BY="Gudrun Paletta">
<TITLE MODIFIED="2008-10-19 16:42:58 +0200" MODIFIED_BY="Gudrun Paletta">Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus</TITLE>
<SUMMARY_BODY MODIFIED="2008-10-19 16:43:05 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Simple application of a single daily insulin injection in addition to oral hypoglycaemic agents may facilitate the initiation of insulin therapy in type 2 diabetes mellitus.This review examined 20 trials including 1,811 participants which compared insulin monotherapy with insulin in combination with oral hypoglycaemic agents (OHA) in insulin-requiring patients with type 2 diabetes. The results suggest that a bedtime NPH insulin-oral hypoglycaemic agent combination therapy regimen provides comparable glycaemic control to insulin monotherapy. Due to lack of studies it remains unclear whether insulin-OHA combination regimens with metformin alone are superior to those with metformin plus a sulphonylurea. In most cases no significant differences in hypoglycaemic events were observed between insulin mono- and OHA combination therapy. No study assessed diabetes-related morbidity or mortality.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-10-03 16:50:55 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>It is unclear whether patients with type 2 diabetes who have poor glycaemic control despite maximal oral hypoglycaemic agents (OHAs) should be commenced on insulin as monotherapy, or insulin combined with oral hypoglycaemic agents (insulin-OHA combination therapy). </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of insulin monotherapy versus insulin-OHA combinations therapy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-10-03 16:50:41 +0200" MODIFIED_BY="[Empty name]">
<P>Eligible studies were identified by searching MEDLINE, EMBASE, and <I>The Cochrane Library</I>. <BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials (RCTs) with 2 months minimum follow-up duration comparing insulin monotherapy (all schemes) with insulin-OHA combination therapy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data extraction and assessment of study quality were undertaken by three reviewers in pairs.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-10-03 16:50:55 +0200" MODIFIED_BY="[Empty name]">
<P>Twenty RCTs (mean trial duration 10 months) including 1,811 participants, with mean age 59.8 years and mean known duration of diabetes 9.6 years. Overall, study methodological quality was low. Twenty-eight comparisons in 20 RCTs were ordered according to clinical considerations. No studies assessed diabetes-related morbidity, mortality or total mortality. From 13 studies (21 comparisons), sufficient data were extracted to calculate pooled effects on glycaemic control. Insulin-OHA combination therapy had statistically significant benefits on glycaemic control over insulin monotherapy only when the latter was applied as a once-daily injection of NPH insulin. Conversely, twice-daily insulin monotherapy (NPH or mixed insulin) provided superior glycaemic control to insulin-OHA combination therapy regimens where insulin was administered as a single morning injection. In more conventional comparisons, regimens utilising OHAs with bedtime NPH insulin provided comparable glycaemic control to insulin monotherapy (administered as twice daily, or multiple daily injections). Overall, insulin-OHA combination therapy was associated with a 43% relative reduction in total daily insulin requirement compared to insulin monotherapy. Of the 14 studies (22 comparisons) reporting hypoglycaemia, 13 demonstrated no significant difference in the frequency of symptomatic or biochemical hypoglycaemia between insulin and combination therapy regimens. No significant differences in quality of life related issues were detected. Combination therapy with bedtime NPH insulin resulted in statistically significantly less weight gain compared to insulin monotherapy, provided metformin was used ± sulphonylurea. In all other comparisons no significant differences with respect to weight gain were detected.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Bedtime NPH insulin combined with oral hypoglycaemic agents provides comparable glycaemic control to insulin monotherapy and is associated with less weight gain if metformin is used. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-28 13:39:25 +0100" MODIFIED_BY="Gudrun Paletta">
<BACKGROUND MODIFIED="2008-10-28 13:39:25 +0100" MODIFIED_BY="Gudrun Paletta">
<CONDITION MODIFIED="2008-10-28 13:09:40 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Diabetes mellitus is a chronic metabolic disorder resulting from a fundamental defect in insulin secretion, insulin action, or both. Consequential chronic hyperglycaemia (i.e. elevated levels of plasma glucose) with associated disturbances of carbohydrate, fat and protein metabolism ensues. Long-term (microvascular) complications of diabetes mellitus include retinopathy, nephropathy and neuropathy. The risk of cardiovascular disease is also increased. For a detailed overview of diabetes mellitus, please see under 'Additional information' in the information on the Metabolic and Endocrine Disorders Group on <I>The Cochrane Library </I>(see 'About the Cochrane Collaboration', 'Collaborative Review Groups-CRGs'). For an explanation of methodological terms, see the main Glossary on <I>The Cochrane Library.</I>
</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-10-28 13:39:25 +0100" MODIFIED_BY="Gudrun Paletta">
<P>In the United Kingdom Prospective Diabetes Study (UKPDS) of newly diagnosed type 2 diabetes patients, compared with conventional therapy, intensive glucose control (mean HbA1c 7.0% versus 7.9%) resulted in a statistically significant 25% relative risk reduction of microvascular complications, and in a non-significant 16% risk reduction of myocardial infarction (<LINK REF="REF-UKPDS-33" TYPE="REFERENCE">UKPDS 33</LINK>). Consequently, most glycaemic management guidelines for type 2 diabetes recommend a target HbA1c less than 7%. Insulin therapy is recommended for patients who are unable to reach this target with oral hypoglycaemic agents alone.</P>
<P>Initial treatment of patients with type 2 diabetes mellitus should be in the form of diet and education. Weight reduction in obese patients and exercise to improve insulin sensitivity and glucose tolerance (<LINK REF="REF-Agurs-1997" TYPE="REFERENCE">Agurs 1997</LINK>; <LINK REF="REF-Bosello-1997" TYPE="REFERENCE">Bosello 1997</LINK>). If non-pharmacological measures are insufficient, additional therapy with oral hypoglycaemic agents is indicated. Later, as oral agents become less efficacious, exogenous insulin, given either as a monotherapy or in combination with (an) oral hypoglycaemic agent(s), may be required.</P>
<P>The UKPDS also demonstrated that despite treatment with a combination of oral agents, a substantial number of patients require insulin therapy to maintain strict glycaemic control (<LINK REF="REF-Turner-1999" TYPE="REFERENCE">Turner 1999</LINK>). The UKPDS did not investigate the use of insulin-oral hypoglycaemic agents (OHA) combination therapy although when patients require insulin, benefit may be obtained from combining insulin with oral hypoglycaemic agents.</P>
<P>Historically, the effects of insulin have been controversial (<LINK REF="REF-Zavaroni-1989" TYPE="REFERENCE">Zavaroni 1989</LINK>; <LINK REF="REF-Stout-1990" TYPE="REFERENCE">Stout 1990</LINK>). The side effects of weight gain and hypoglycaemia are well known, though it was also long thought that exogenous insulin was a causative risk factor for cardiovascular complications. The UKPDS and other studies have found no evidence for this (<LINK REF="REF-Ruige-1998" TYPE="REFERENCE">Ruige 1998</LINK>). It is also uncertain if, and how, insulin therapy may influence 'quality of life' and patient treatment satisfaction. Improving glycaemia per se may improve general well-being, however, daily injections with insulin, home monitoring of blood glucose, episodes of hypoglycaemia and referral from primary to secondary care can interfere with the daily functioning of patients (<LINK REF="REF-de-Sonnaville-1998" TYPE="REFERENCE">de Sonnaville 1998</LINK>, <LINK REF="REF-Goddijn-1999" TYPE="REFERENCE">Goddijn 1999</LINK>, <LINK REF="REF-van-der-Does-1996" TYPE="REFERENCE">van der Does 1996</LINK>).</P>
<P>Three previous reviews comparing insulin monotherapy to insulin / oral hypoglycaemic agent combination therapy have focused on insulin combined with sulphonylureas or placebo, excluding other groups of oral agents (<LINK REF="REF-Peters-1991" TYPE="REFERENCE">Peters 1991</LINK>; <LINK REF="REF-Pugh-1992" TYPE="REFERENCE">Pugh 1992</LINK>; <LINK REF="REF-Johnson-1996" TYPE="REFERENCE">Johnson 1996</LINK>). These reviews included studies where either insulin-treated patients were randomised to the addition of a sulphonylurea or placebo, or where insulin-requiring patients with poor glycaemic control despite oral hypoglycaemic agents were randomised to receive insulin combined with sulphonylurea therapy, or insulin alone. These reviews were of limited design and did not explicitly address the aim of the present study, namely to determine the optimum initial insulin treatment strategy for insulin-requiring type 2 patients. Despite the apparent similarities of these reviews, the authors' conclusions differed. <LINK REF="REF-Peters-1991" TYPE="REFERENCE">Peters 1991</LINK>concluded that combination therapy should not be used in insulin-treated patients with type 2 diabetes since improvement was only slight and blood glucose values were not normalised with this therapy. The later reviews of <LINK REF="REF-Pugh-1992" TYPE="REFERENCE">Pugh 1992</LINK> and <LINK REF="REF-Johnson-1996" TYPE="REFERENCE">Johnson 1996</LINK> however, recommended insulin / sulphonylurea combination therapy, finding it to be more efficacious than insulin alone.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2008-10-28 13:10:14 +0100" MODIFIED_BY="Gudrun Paletta">
<P>
<LINK REF="REF-Yki_x002d_J_x00e4_rvinen-2001" TYPE="REFERENCE">Yki-Järvinen 2001</LINK> published a fairly comprehensive overview of studies on insulin-OHA combination therapies, though this review did not meet the criteria of the Cochrane Collaboration. Therefore, an up-to-date systematic review conforming to the methods of the Cochrane Collaboration was undertaken to clarify the potential benefits of combination therapy compared to insulin monotherapy.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of insulin monotherapy versus insulin-oral hypoglycaemic agents combination therapy. </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-28 13:12:13 +0100" MODIFIED_BY="Gudrun Paletta">
<SELECTION_CRITERIA MODIFIED="2008-10-28 13:10:48 +0100" MODIFIED_BY="Gudrun Paletta">
<CRIT_STUDIES>
<P>Randomised controlled trials (RCTs of any design) with a minimum follow-up duration of two months. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-10-03 17:22:37 +0200" MODIFIED_BY="[Empty name]">
<P>Patients with type 2 diabetes mellitus (according to appropriate diagnostic criteria of the time) and inadequate glycaemic control despite oral hypoglycaemic agents. To be consistent with changes in classification and diagnostic criteria of the disease, the diagnosis should have been established using the standard criteria valid at the outset of the trial (<LINK REF="REF-NDDG-1979" TYPE="REFERENCE">NDDG 1979</LINK>; <LINK REF="REF-WHO-1980" TYPE="REFERENCE">WHO 1980</LINK>; <LINK REF="REF-WHO-1985" TYPE="REFERENCE">WHO 1985</LINK>; <LINK REF="REF-ADA-1997" TYPE="REFERENCE">ADA 1997</LINK>; <LINK REF="REF-ADA-1999" TYPE="REFERENCE">ADA 1999</LINK>; <LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>). Since changes in diagnostic criteria may produce significant variability in the clinical characteristics of the patients included as well as in the results obtained, these differences were considered and later explored in a sensitivity analysis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The following possible types of interventions and comparisons were included: <BR/>Insulin monotherapy compared to combinations of insulin with single or multiple oral hypoglycaemic agents.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-28 13:10:48 +0100" MODIFIED_BY="Gudrun Paletta">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-03 16:55:29 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>any diabetes-related morbidity: myocardial infarction, angina, heart failure, stroke, renal failure, amputation (of at least one digit), vitreous haemorrhage, retinal photocoagulation, blindness in one eye, or cataract extraction;</LI>
<LI>Glycaemic control (fasting blood glucose, HbA1, HbA1c).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-28 13:10:48 +0100" MODIFIED_BY="Gudrun Paletta">
<UL>
<LI>quality of life (ideally using validated scales);</LI>
<LI>patient satisfaction (ideally using validated scales);</LI>
<LI>amount of insulin necessary for good glycaemic control;</LI>
<LI>adverse effects: incidence of hypoglycaemia, weight gain, gastrointestinal symptoms.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Timing of outcome measurement</HEADING>
<UL>
<LI>short-term: 2 - 6 months;</LI>
<LI>intermediate-term: greater than 6 to 12 months;</LI>
<LI>long-term: more than 12 months.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-28 13:11:31 +0100" MODIFIED_BY="Gudrun Paletta">
<ELECTRONIC_SEARCHES MODIFIED="2008-10-28 13:11:31 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Electronic search strategies were used to identify relevant trials (as specified under 'types of studies') and reviews/meta-analyses (for identification of additional trials). The following databases were searched:</P>
<UL>
<LI>
<I>The Cochrane Library</I> (issue 2, 2004; including the Cochrane Controlled Trials Register (CCTR) and the Database of Reviews of Effectiveness (DARE);</LI>
<LI>MEDLINE (1966 to 05/2004);</LI>
<LI>EMBASE (1974 to 05/2004).</LI>
</UL>
<P>
<BR/>We also searched databases of ongoing trials:<BR/>
</P>
<UL>
<LI>Current Controlled Trials (www.controlled-trials.com);</LI>
<LI>The National Research Register (www.update-software.com/National/nrr-frame.html).</LI>
</UL>
<P/>
<P>One reviewer (ANG) searched the following computerised bibliographic databases: <I>The Cochrane Library</I>, MEDLINE and EMBASE, with no language restriction. For detailed search strategies please see under <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. Relevant published studies of any language were included. The reference lists of relevant trials and reviews identified were also scrutinised to identify other potentially relevant studies.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-28 13:12:13 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDY_SELECTION MODIFIED="2008-10-03 17:02:54 +0200" MODIFIED_BY="[Empty name]">
<P>References identified from searches were entered into Reference Manager 10. To determine the studies to be assessed further, two independent reviewers (ANG, GDV) scanned titles, abstract and keywords of every record retrieved. Full articles were retrieved for further assessment if the information given suggested that the study:</P>
<UL>
<LI>included patients with type 2 diabetes mellitus;</LI>
<LI>compared insulin with a combination of insulin with (an) oral hypoglycaemic agent(s);</LI>
<LI>assessed one or more relevant clinical outcome measure;</LI>
<LI>used random allocation to comparison groups.</LI>
</UL>
<P>Where details regarding these criteria were inadequate from the information given in the title and abstract, the full article was retrieved for clarification. Interrater agreement for study selection was measured using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>). Differences in opinion were discussed with a third party (RPS). Where resolution of disagreement was not possible, the article was added to those 'awaiting assessment' and the authors contacted for clarification. When no clarification was provided, the review group editorial base would have been consulted. If the results of a trial were reported in separate articles data were appropriately combined and analysed as one study.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-10-03 17:04:13 +0200" MODIFIED_BY="[Empty name]">
<P>Three reviewers (ANG, GDV, NF) independently extracted the data including:</P>
<UL>
<LI>general information: published/unpublished, title, authors, reference/source, contact address, country, urban/rural etc., language of publication, year of publication, duplicate publications, sponsoring, setting.</LI>
<LI>trial characteristics: design, duration, randomisation (and method), allocation concealment (and method), blinding (patients, people administering treatment, outcome assessors), assessment of blinding.</LI>
<LI>intervention(s): placebo included, interventions(s) (dose, route, timing), comparison intervention(s) (dose, route, timing).</LI>
<LI>patients: sampling (random/convenience), exclusion criteria, total number and number in comparison groups, sex, age, duration of diabetes, similarity of groups at baseline (including any co-morbidity), assessment of compliance, withdrawals / losses to follow-up (reasons/description), subgroups.</LI>
<LI>outcomes: outcomes specified above (also: what was the main outcome assessed in the study?), any other outcomes assessed, other events, length of follow-up, quality of reporting of outcomes.</LI>
<LI>results: for outcomes and times of assessment (including a measure of variation), if necessary converted to measures of effect specified below; intention-to-treat analysis.</LI>
</UL>
<P>A template data extraction form was developed, piloted and approved by the Metabolic and Endocrine Disorders Group Editorial Base before final data extraction commenced. Data extraction and data entry were performed independently in pairs (ANG / GDV and ANG / NF). Differences in data extraction were resolved by consensus with the fourth reviewer (RPS), with referral to the original article. Where the published report contained incomplete (or absent) data (see data extraction list), the reviewers contacted the first author using the standard letter from the Editorial Base.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-10-28 13:11:59 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Each trial was independently assessed by two reviewers (ANG, GDV). Interrater agreement was calculated using the kappa statistic. In cases of disagreement, the Cochrane Metabolic and Endocrine Disorders Group would have been consulted and a judgement made based on consensus.</P>
<P>The trials were assessed on methodological quality using a selection of the 17-item Maastricht- Amsterdam Criteria List (<LINK REF="REF-Van-Tulder-1997" TYPE="REFERENCE">Van Tulder 1997</LINK>), which includes criteria of Jadad (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) and Schulz (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). The following factors were scored (total score range from 0 - 7):<BR/>1. Minimisation of selection bias - a) was the randomisation procedure adequate? b) was the allocation concealment adequate?<BR/>2. Minimisation of performance bias - were a) the patients and b) people administering the treatment blind to the intervention?<BR/>3. Minimisation of attrition bias - a) were withdrawals and dropouts completely described? b) was analysis by intention-to-treat?<BR/>4. Minimisation of detection bias - were a) outcome assessors blind to the intervention?</P>
<P>Based on these criteria, studies were subdivided into three categories:<BR/>A - all quality criteria met: low risk of bias.<BR/>B - one or more of the quality criteria only partly met: moderate risk of bias.<BR/>C - one or more criteria not met: high risk of bias.<BR/>This classification was used as the basis for a sensitivity analysis. The influence of individual quality criteria were also used in sensitivity analyses. Studies were not excluded on the basis of methodological criteria alone.</P>
</QUALITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-10-03 17:06:48 +0200" MODIFIED_BY="[Empty name]">
<P>Small study bias was evaluated by using a funnel plot method (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-10-28 13:12:13 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Available data were included in a meta-analysis if they were sufficiently similar and of sufficient quality. For dichotomous data the results are expressed as odds ratios (OR) with corresponding 95% confidence intervals (95% CIs), and continuous data as weighted mean difference with 95% CIs, or as standardised weighted mean difference where outcomes were conceptually the same but measured in different ways (<LINK REF="REF-Rosenthal-1994" TYPE="REFERENCE">Rosenthal 1994</LINK>; <LINK REF="REF-Mulrow-1997" TYPE="REFERENCE">Mulrow 1997</LINK>; <LINK REF="REF-Lau-1997" TYPE="REFERENCE">Lau 1997</LINK>). Where studies that did not provide HbA1c change-from-baseline values, these data were computed from baseline and post-treatment values, eventually distracted from graphs. When standard deviations of mean differences for the main outcome HbA1c were not provided in the publications, these data were computed assuming a general correlation coefficient that was derived from baseline and post-treatment outcomes for HbA1c in studies that presented accompanying SDs (see below). Glycated haemoglobin values determined with different methodologies were standardized to a reference range of 4.0 to 6.0 % (<LINK REF="REF-Little-1986" TYPE="REFERENCE">Little 1986</LINK>; <LINK REF="REF-DCCT-1993" TYPE="REFERENCE">DCCT 1993</LINK>). Insulin requirement in combination therapy regimens was expressed as a relative reduction in insulin dose compared to monotherapy, expressed as percentage (unweighted mean; 95% CI). Differences underlying the results of studies (statistical heterogeneity) were assessed using both the Q-test (with a P-value less than 0.1 considered as significant) and by I-squared<SUP> </SUP>(<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Clinical heterogeneity was surveyed by comparing the studies with regard to different clinical parameters: patient characteristics (e.g. previous treatment), disease duration, interventions and outcome. Where significant clinical or statistical heterogeneity was found, it was considered unreasonable to assume one 'true' effect underlying the data constant across different populations, necessitating a random-effects model to pool data. (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>).</P>
<P>For each study the mean changes from baseline and standard deviations of the outcome HbA1[c] were extracted, if available. If not available, mean change scores of HbA1[c] were calculated by subtracting baseline from post-treatment values. Matching standard deviations were computed in SPSS 11.0 with a formula (formula 1), which included a general correlation coefficient between baseline and post-treatment values of HbA1[c] of 0.5. This figure was set 0.1 point lower than the correlation coefficient that was calculated from studies that provided information on change scores inclusive standard deviations, and which appeared to be 0.6 in most studies (formula 2) (<LINK REF="REF-Armitage-2002" TYPE="REFERENCE">Armitage 2002</LINK>).</P>
<P>
<I>Formula 1: SPSS syntax for computing standard deviations of changes from baseline values of HbA1[c]</I>
<BR/>SD = sqrt(sd_tr_b**2 + sd_tr_p**2 - 2 * corr * sd_tr_b * sd_tr_p).</P>
<P>abbreviations:<BR/>sd = standard deviation<BR/>Sqrt = square root<BR/>sd_tr_b = standard deviation of mean baseline HbA1[c]<BR/>sd_tr_p = standard deviation of mean post treatment HbA1[c]<BR/>corr = correlation coefficient between baseline and post-treatment values of HbA1[c]</P>
<P>
<I>Formula 2: SPSS syntax for computing correlation coefficient between baseline and post-treatment values of HbA1[c]</I>
<BR/>corr_tr = (sd_tr_b**2 + sd_tr_p**2 - sddiff_tr**2) / (2*sd_tr_b*sd_tr_p).</P>
<P>Abbreviations:<BR/>corr_tr = correlation coefficient between baseline and post-treatment values of HbA1[c]<BR/>sd_tr_b = standard deviation of mean baseline HbA1[c]<BR/>sd_tr_p = standard deviation of mean post treatment HbA1[c]<BR/>sddiff_tr = standard deviation of change from baseline HbA1[c]</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-10-03 17:06:00 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup analyses were planned for the following variables: different oral hypoglycaemic agent(s) and different types of insulin, timing and frequency of insulin injections.<BR/>
</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-10-03 17:06:33 +0200" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses were planned to explore the influence of the following factors on effect size:</P>
<UL>
<LI>repeating the analysis excluding unpublished studies.</LI>
<LI>repeating the analysis taking account of study quality, as specified above.</LI>
<LI>repeating the analysis excluding any very long or large studies to establish how much they dominate the results.</LI>
</UL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-28 13:35:39 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDY_DESCRIPTION MODIFIED="2008-10-28 13:18:02 +0100" MODIFIED_BY="Gudrun Paletta">
<SEARCH_RESULTS MODIFIED="2008-10-28 13:15:50 +0100" MODIFIED_BY="Gudrun Paletta">
<P>The search strategy provided 1,709 citations. After exclusion of doubles and studies not related to the objective of the review, two reviewers independently assessed the remaining 192 abstracts. Full text was obtained of 127 potentially relevant studies, of which 22 fulfilled the inclusion criteria of the review. Three studies found after the last search are waiting for assessment and will be included in the first update of this review (<LINK REF="STD-Olsson-2002" TYPE="STUDY">Olsson 2002</LINK>; <LINK REF="STD-Stehouwer-2003" TYPE="STUDY">Stehouwer 2003</LINK>; <LINK REF="STD-Goudswaard-2004" TYPE="STUDY">Goudswaard 2004</LINK>).</P>
<P/>
<SUBSECTION>
<HEADING LEVEL="4">Interrater agreement</HEADING>
<P>The observed agreement in trial selection was 94% (kappa = 0.71; 95% CI 0.56 to 0.86). For unclear cases agreement was reached by reading the article together, followed by discussion. The observed overall agreement in the extraction of the data was 95%. After discussion all disagreements were resolved.</P>
<P/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Missing data</HEADING>
<P>We contacted Chow, Fövényi, Holman, and Pontiroli for further details regarding their studies; all provided further information (<LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK>; <LINK REF="STD-F_x00f6_v_x00e9_nyi-1997" TYPE="STUDY">Fövényi 1997</LINK>; <LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>; <LINK REF="STD-Pontiroli-1990" TYPE="STUDY">Pontiroli 1990</LINK>).</P>
<P>
<BR/>
</P>
</SUBSECTION>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-10-28 13:18:02 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Twenty RCTs described in 22 articles met the inclusion criteria. The results of two RCTs were reported in four separate articles. Data from these duplicate publications were appropriately combined (<LINK REF="STD-Gutniak-1987" TYPE="STUDY">Gutniak 1987</LINK>; <LINK REF="STD-Karlander-1991" TYPE="STUDY">Karlander 1991</LINK>, <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>; <LINK REF="STD-M_x00e4_kimattila-1999" TYPE="STUDY">Mäkimattila 1999</LINK>) and thus analysed as two studies (<LINK REF="STD-Gutniak-1987" TYPE="STUDY">Gutniak 1987</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>). Fifteen articles (75%) were published in English, three in German (<LINK REF="STD-Bachmann-1988" TYPE="STUDY">Bachmann 1988</LINK>; <LINK REF="STD-Lotz-1988" TYPE="STUDY">Lotz 1988</LINK>; <LINK REF="STD-Lundershausen-1987" TYPE="STUDY">Lundershausen 1987</LINK>), one in Dutch (<LINK REF="STD-Wolffenbuttel-1991" TYPE="STUDY">Wolffenbuttel 1991</LINK>), one in Hungarian (<LINK REF="STD-F_x00f6_v_x00e9_nyi-1997" TYPE="STUDY">Fövényi 1997</LINK>), and two in Chinese (<LINK REF="STD-Sun-1995" TYPE="STUDY">Sun 1995</LINK>, <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>). No eligible trials were found before the year 1987. At least 50% of the studies were sponsored by the pharmaceutical industry.</P>
<P>
<I>

</I>
</P>
<SUBSECTION>
<HEADING LEVEL="4">Studies and participants</HEADING>
<P>All 20 included studies were randomised controlled studies, of which 16 had a parallel design, and four a crossover design (<LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>; <LINK REF="STD-Riddle-1998" TYPE="STUDY">Riddle 1998</LINK>; <LINK REF="STD-Pontiroli-1990" TYPE="STUDY">Pontiroli 1990</LINK>; <LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK>). Weighted mean trial duration was 10.0 months (range 2 to 36 months). A total of 1811 participants (mean per study 91; range 10 to 432) were included in these studies, with 46% men (range 29% to 64%). Gender was not reported in five trials (<LINK REF="STD-Gutniak-1987" TYPE="STUDY">Gutniak 1987</LINK>; <LINK REF="STD-Lotz-1988" TYPE="STUDY">Lotz 1988</LINK>; <LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK>; <LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK>; <LINK REF="STD-Shank-1995" TYPE="STUDY">Shank 1995</LINK>). Participants had mean age of 59.8 years (95% CI 57.6 to 62.1), and mean known duration of diabetes was 9.6 years (95% CI 8.3 to 10.9). All studies provided information on oral hypoglycaemic therapy at baseline. Further details and criteria for entry into the individual studies are listed in the Table "Characteristics of included studies".</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Study settings</HEADING>
<P>In one study patients were recruited in primary care (<LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>), all other studies were conducted in secondary care. In three studies patients were admitted to hospital for baseline measurements and initiation of insulin therapy (<LINK REF="STD-Gutniak-1987" TYPE="STUDY">Gutniak 1987</LINK>; <LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>).</P>
<P>
<I>

</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Study characteristics</HEADING>
<P>Twenty studies providing 28 comparisons between insulin monotherapy and insulin-oral hypoglycaemic agent combination regimens were evaluated. In both monotherapy and combination therapy groups, insulin was applied as a once-daily (morning or bedtime), twice-daily, or a multiple-daily injection regimen. Oral hyperglycaemic agents utilised included sulphonylureas (75%), metformin (4%) or both (21%). Comparisons were initially categorised according to mode of insulin monotherapy, and subsequently sub-categorised according to combination therapy regimen used, to provide clinically relevant comparisons:<BR/>1) Insulin monotherapy (once-daily injection) versus combination regimens (<LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>; <LINK REF="STD-Lundershausen-1987" TYPE="STUDY">Lundershausen 1987</LINK>; <LINK REF="STD-Pontiroli-1990" TYPE="STUDY">Pontiroli 1990</LINK>; <LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK>; <LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK>; <LINK REF="STD-Riddle-1998" TYPE="STUDY">Riddle 1998</LINK>; <LINK REF="STD-Shank-1995" TYPE="STUDY">Shank 1995</LINK>; <LINK REF="STD-Sun-1995" TYPE="STUDY">Sun 1995</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>).<BR/>2) Insulin monotherapy (twice-daily injection) versus combination regimens (<LINK REF="STD-Bachmann-1988" TYPE="STUDY">Bachmann 1988</LINK>; <LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK>; <LINK REF="STD-F_x00f6_v_x00e9_nyi-1997" TYPE="STUDY">Fövényi 1997</LINK>; <LINK REF="STD-Gutniak-1987" TYPE="STUDY">Gutniak 1987</LINK>; <LINK REF="STD-Lotz-1988" TYPE="STUDY">Lotz 1988</LINK>; <LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK>; <LINK REF="STD-Wolffenbuttel-1991" TYPE="STUDY">Wolffenbuttel 1991</LINK>; <LINK REF="STD-Wolffenbuttel-1996" TYPE="STUDY">Wolffenbuttel 1996</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>).<BR/>3) Insulin monotherapy (multiple-daily injections) versus combination regimens (<LINK REF="STD-Bastyr-1999" TYPE="STUDY">Bastyr 1999</LINK>; <LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>).</P>
<P>
<I>

</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome measures</HEADING>
<P>No studies assessed diabetic complications, diabetes-related mortality or total mortality.<BR/>All except three studies (<LINK REF="STD-Lundershausen-1987" TYPE="STUDY">Lundershausen 1987</LINK>, <LINK REF="STD-Bachmann-1988" TYPE="STUDY">Bachmann 1988</LINK>; <LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK>) reported glycaemic control as mean values of HbA<SUB>1 </SUB>(<LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>; <LINK REF="STD-Lotz-1988" TYPE="STUDY">Lotz 1988</LINK>; <LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK>; <LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK>) or HbA<SUB>1c</SUB>. Five studies provided change-from-baseline values for glycated haemoglobin with standard deviations (<LINK REF="STD-Bastyr-1999" TYPE="STUDY">Bastyr 1999</LINK>; <LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK>; <LINK REF="STD-Riddle-1998" TYPE="STUDY">Riddle 1998</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>). Fasting blood glucose values were not reported in two studies (<LINK REF="STD-F_x00f6_v_x00e9_nyi-1997" TYPE="STUDY">Fövényi 1997</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>). Three studies did not provide the method of analysis for glycated haemoglobin (<LINK REF="STD-Sun-1995" TYPE="STUDY">Sun 1995</LINK>; <LINK REF="STD-Bastyr-1999" TYPE="STUDY">Bastyr 1999</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>).<BR/>Seven studies (13 comparisons) provided change-from-baseline values for body weight with standard deviations (<LINK REF="STD-Bastyr-1999" TYPE="STUDY">Bastyr 1999</LINK>; <LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK>; <LINK REF="STD-F_x00f6_v_x00e9_nyi-1997" TYPE="STUDY">Fövényi 1997</LINK>; <LINK REF="STD-Gutniak-1987" TYPE="STUDY">Gutniak 1987</LINK>; <LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>).<BR/>Insulin requirement was reported in all but three studies (<LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK>; <LINK REF="STD-Sun-1995" TYPE="STUDY">Sun 1995</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>).<BR/>Patient satisfaction, general well-being or quality of life was assessed in three studies (<LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK>; <LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>).<BR/>All but seven studies (<LINK REF="STD-F_x00f6_v_x00e9_nyi-1997" TYPE="STUDY">Fövényi 1997</LINK>; <LINK REF="STD-Lundershausen-1987" TYPE="STUDY">Lundershausen 1987</LINK>; <LINK REF="STD-Pontiroli-1990" TYPE="STUDY">Pontiroli 1990</LINK>; <LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK>; <LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK>; <LINK REF="STD-Wolffenbuttel-1991" TYPE="STUDY">Wolffenbuttel 1991</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>) in some way provided information on hypoglycaemic events, although only three (<LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>) provided number of hypoglycaemic events with standard deviations.<BR/>Other adverse effects were reported in two studies (<LINK REF="STD-Bastyr-2000" TYPE="STUDY">Bastyr 2000</LINK>; <LINK REF="STD-Riddle-1998" TYPE="STUDY">Riddle 1998</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2008-10-28 13:14:46 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Reasons for exclusion of studies are given in 'Table of excluded studies'. Main reasons for exclusion were: Patients were previously treated with insulin (n = 47), absence of a treatment arm with either monotherapy with insulin or with a combination of insulin with oral hypoglycaemic agents (n = 32), a non-appropriate study design (n = 12), and "other reasons" (n=14).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-10-28 13:19:41 +0100" MODIFIED_BY="Gudrun Paletta">
<P>The methodological quality scores of the included studies (scale range 0 (min) to 7 (max)) were assigned using the criteria described above, and are listed in the table of included studies. Only information published in the trials was used to determine a quality score. Inter-observer calculation of the items of study quality revealed a substantial observed agreement of 82% (kappa = 0.62; 95% CI 0.48 to 0.76). Mean study quality was 2.6 (95% CI 1.5 to 3.7). Mean patients' drop-out rate was 5.5%. Disregarding one study with a drop-out rate of 51% (<LINK REF="STD-Bachmann-1988" TYPE="STUDY">Bachmann 1988</LINK>), mean drop-out rate was only 1.4%. None of the studies reported a power calculation. Of the four cross-over studies none had a wash-out period, and two analysed data for carryover and period effects. Inclusion criteria were not described in four studies (<LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>; <LINK REF="STD-Lundershausen-1987" TYPE="STUDY">Lundershausen 1987</LINK>; <LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>). In most studies patients with co-morbidity and diabetes complications were excluded.</P>
<ALLOCATION MODIFIED="2008-10-28 13:18:53 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Eight studies detailed the method of randomisation (<LINK REF="STD-Bastyr-2000" TYPE="STUDY">Bastyr 2000</LINK>; <LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK>; <LINK REF="STD-Lotz-1988" TYPE="STUDY">Lotz 1988</LINK>; <LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK>; <LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK>; <LINK REF="STD-Shank-1995" TYPE="STUDY">Shank 1995</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>), although in two trials the method could not be considered as adequate (<LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK>; <LINK REF="STD-Lotz-1988" TYPE="STUDY">Lotz 1988</LINK>). Fifteen studies (75%) had inadequate or unclear allocation concealment, and in five studies allocation concealment was adequate (<LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK>; <LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK>; <LINK REF="STD-Riddle-1998" TYPE="STUDY">Riddle 1998</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2008-10-28 13:19:40 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Stated method of blinding was open in eleven studies, single-blinding in two, double-blinding in three, and triple-blinding in four. None of the studies reported checked blinding conditions in patients and health care providers.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2008-10-28 13:19:28 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Seventy per cent of studies reported drop-outs in some detail. Intention-to-treat analyses were described in six studies.</P>
<P/>
</EXCLUSIONS>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-28 13:35:39 +0100" MODIFIED_BY="Gudrun Paletta">
<P>For details see <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>.</P>
<P/>
<SUBSECTION>
<HEADING LEVEL="3">Glycaemic control (glycosylated haemoglobin)</HEADING>
<P>Comparisons were initially categorised according to mode of insulin monotherapy (once-daily, twice-daily, or multiple-daily injections), and subsequently sub-categorised according to combination therapy regimen used, to provide clinically useful subgroups as pre-planned. From thirteen studies (21 comparisons) sufficient data were extracted to calculate pooled effects on glycaemic control.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3"/>
<SUBSECTION>
<HEADING LEVEL="4">Once-daily insulin monotherapy regimens</HEADING>
<P>In nine comparisons, insulin monotherapy applied as either a single morning (<LINK REF="STD-Pontiroli-1990" TYPE="STUDY">Pontiroli 1990</LINK>) or evening injection (<LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>; <LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK>; <LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK>; <LINK REF="STD-Riddle-1998" TYPE="STUDY">Riddle 1998</LINK>; <LINK REF="STD-Shank-1995" TYPE="STUDY">Shank 1995</LINK>; <LINK REF="STD-Sun-1995" TYPE="STUDY">Sun 1995</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>) was compared with a matching insulin injection combined with a sulphonylurea (SU). One study (<LINK REF="STD-Lundershausen-1987" TYPE="STUDY">Lundershausen 1987</LINK>) provided no information on timing of insulin injections. Data from five comparisons comparing a single evening insulin injection to evening insulin combined with daytime sulphonylurea were pooled in a meta-analysis (<LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK>; <LINK REF="STD-Riddle-1998" TYPE="STUDY">Riddle 1998</LINK>; <LINK REF="STD-Shank-1995" TYPE="STUDY">Shank 1995</LINK>; <LINK REF="STD-Sun-1995" TYPE="STUDY">Sun 1995</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>). Insulin-oral hypoglycaemic agents (OHA) combination therapy was associated with a significant mean (pooled weighted mean difference) lowering of HbA1c of 0.3% (95% CI 0.0 to 0.6; P = 0.03) compared to insulin monotherapy. Heterogeneity was low (I<SUP>2 </SUP>= 16,3%; Chi<SUP>2</SUP> = 4.8; P = 0.31) Four comparisons were not included in the meta-analysis. <LINK REF="STD-Lundershausen-1987" TYPE="STUDY">Lundershausen 1987</LINK> reported no outcome data for HbA1(c), and three cross-over studies with heterogeneous design had potential carryover effect for HbA1(c) (<LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>; <LINK REF="STD-Pontiroli-1990" TYPE="STUDY">Pontiroli 1990</LINK>; <LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK>). <LINK REF="STD-Pontiroli-1990" TYPE="STUDY">Pontiroli 1990</LINK> and <LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK> reported better glycaemic control with combination therapy, whereas <LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK> and <LINK REF="STD-Lundershausen-1987" TYPE="STUDY">Lundershausen 1987</LINK> found no difference compared with insulin monotherapy.<BR/>
<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Twice-daily insulin monotherapy regimens</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Bedtime neutral protamine Hagedorn (NPH) insulin plus oral hypoglycaemic agents</HEADING>
<P>In seven comparisons, twice-daily insulin monotherapy was compared with bedtime NPH combined with either SU (1) (<LINK REF="STD-F_x00f6_v_x00e9_nyi-1997" TYPE="STUDY">Fövényi 1997</LINK>; <LINK REF="STD-Wolffenbuttel-1996" TYPE="STUDY">Wolffenbuttel 1996</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>), metformin (2) (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>), or SU plus metformin (3) (<LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>).</P>
<P/>
<SUBSECTION>
<HEADING LEVEL="6">Bedtime NPH plus SU (three comparisons)</HEADING>
<P>Insulin-OHA combination therapy was associated with a non-significant mean (pooled weighted mean difference) lowering of HbA1c of 0.1% (95% CI -0.9 to 1.1; P = 0.87) compared to insulin monotherapy. Heterogeneity was high (I<SUP>2 </SUP>= 90.4%; Chi<SUP>2 </SUP>= 20.9; P &lt; 0.0001). After elimination of one large study of poor quality (<LINK REF="STD-F_x00f6_v_x00e9_nyi-1997" TYPE="STUDY">Fövényi 1997</LINK>) insulin monotherapy was associated with a non-significant mean (pooled weighted mean difference) lowering of HbA1c of 0.4% (95% CI -0.9 to 0.1; P = 0.08) compared to insulin-OHA combination therapy. There was no statistically significant heterogeneity (I<SUP>2 </SUP>= 0%; Chi<SUP>2 </SUP>= 0.81; P = 0.37).</P>
<P/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Bedtime NPH plus metformin (one comparison)</HEADING>
<P>Insulin-OHA combination therapy was associated with a significant mean lowering of HbA1c of 0.6% (P &lt; 0.05) compared to insulin monotherapy.</P>
<P/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Bedtime NPH plus SU plus metformin (three comparisons)</HEADING>
<P>Insulin monotherapy was associated with a non-significant mean (pooled weighted mean difference) lowering of HbA1c of 0.2% (95% CI -0.7 to 0.4; P = 0.54) compared to insulin-OHA combination therapy. Heterogeneity was moderate (I<SUP>2 </SUP>= 33.1%; Chi<SUP>2 </SUP>= 2.99; P = 0.22). Elimination of one study of poor quality (<LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK>) did not change this result.</P>
<P/>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Morning NPH insulin plus oral hypoglycaemic agents</HEADING>
<P>In four comparisons, twice-daily insulin monotherapy was compared with morning NPH insulin combined with SU (<LINK REF="STD-Lotz-1988" TYPE="STUDY">Lotz 1988</LINK>; <LINK REF="STD-Wolffenbuttel-1991" TYPE="STUDY">Wolffenbuttel 1991</LINK>; <LINK REF="STD-Wolffenbuttel-1996" TYPE="STUDY">Wolffenbuttel 1996</LINK>) or SU plus metformin (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>). Insulin monotherapy was associated with a significant mean (pooled weighted mean difference) lowering of HbA1c of 0.4% (95% CI 0.1 to 0.8; P = 0.03) compared to insulin-OHA combination therapy. There was no statistically significant heterogeneity (I<SUP>2 </SUP>= 0%; Chi<SUP>2 </SUP>= 1.5; P = 0.68).</P>
<P>

</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Twice-daily insulin plus oral hypoglycaemic agents</HEADING>
<P>In three comparisons, insulin monotherapy was compared with twice-daily (morning plus bedtime) premixed insulin 30/70 combined with SU (<LINK REF="STD-Bachmann-1988" TYPE="STUDY">Bachmann 1988</LINK>; <LINK REF="STD-Gutniak-1987" TYPE="STUDY">Gutniak 1987</LINK>; <LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK>). <LINK REF="STD-Bachmann-1988" TYPE="STUDY">Bachmann 1988</LINK> and <LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK> reported HbA1(c) as median values. <LINK REF="STD-Gutniak-1987" TYPE="STUDY">Gutniak 1987</LINK> and <LINK REF="STD-Bachmann-1988" TYPE="STUDY">Bachmann 1988</LINK> found no statistically significant difference between monotherapy and combination therapy, and <LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK> found a significant lower HbA1c for combination therapy (P &lt; 0.05).<BR/>
<B>
<BR/>
</B>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Multiple daily insulin injections</HEADING>
<P>In two comparisons (<LINK REF="STD-Bastyr-1999" TYPE="STUDY">Bastyr 1999</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>), a multiple insulin injection regimen (pre-meal soluble insulin with bedtime NPH) was compared to bedtime NPH insulin combined with SU or SU plus metformin. Insulin-OHA combination therapy was associated with a non-significant mean (pooled weighted mean difference) lowering of HbA1c of 0.2% (95% CI -0.4 to 0.1; P = 0.30) compared to insulin monotherapy. There was no statistically significant heterogeneity (I<SUP>2 </SUP>= 0%; Chi<SUP>2 </SUP>= 0.42; P = 0.48).<BR/>In two comparisons, similar multiple injection regimens were compared with morning ultralente (<LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>) or NPH insulin (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>) combined with SU. In both studies mean decrease of HbA1 was not significantly different between regimens. One study compared a multiple insulin injection regimen with a matching multiple injection regimen combined with SU (<LINK REF="STD-Bastyr-1999" TYPE="STUDY">Bastyr 1999</LINK>). Mean decrease of HbA1c did not significantly differ between regimens.</P>
<P>

</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<P>In a subgroup analysis we combined studies that included metformin (± SU) in insulin-OHA combination therapy (<LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>). Of <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK> we included the most successful of three comparisons, for which analysis was not pre-planned. No significant difference was found of insulin-OHA combination therapy over insulin monotherapy. This did not change after excluding one study of lower quality (<LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analyses</HEADING>
<P>Since only published studies were included in this review pre-planned analyses excluding unpublished trials were not performed. Repeating analyses excluding one large trial with poor quality and another trial of poor quality did not significantly alter the results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Small study bias</HEADING>
<P>For the outcome glycaemic control (HbA1(c)) we graphically evaluated a funnel plots of comparison 02.01. Visual assessment indicates small study bias (Funnel plot <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Other comparisons included too few studies for assessment of bias by funnel plots.</P>
<P/>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hypoglycaemia</HEADING>
<P>Hypoglycaemia was reported quantitatively or qualitatively in all but six studies (<LINK REF="STD-F_x00f6_v_x00e9_nyi-1997" TYPE="STUDY">Fövényi 1997</LINK>; <LINK REF="STD-Lundershausen-1987" TYPE="STUDY">Lundershausen 1987</LINK>; <LINK REF="STD-Pontiroli-1990" TYPE="STUDY">Pontiroli 1990</LINK>; <LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK>; <LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>). Heterogeneity in the definitions used between studies, and the quality of reporting of hypoglycaemia precluded the pooling of data. Of the fourteen studies (22 comparisons) that reported hypoglycaemia, in all but one comparison (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>), no significant difference in the frequency of hypoglycaemic events (symptomatic or biochemical) between insulin monotherapy and insulin-OHA combination therapy was demonstrated. Overall, only one episode of severe hypoglycaemia (requiring third party assistance) was reported (<LINK REF="STD-Wolffenbuttel-1996" TYPE="STUDY">Wolffenbuttel 1996</LINK>).</P>
<P>

</P>
<SUBSECTION>
<HEADING LEVEL="4">Once-daily insulin monotherapy regimens </HEADING>
<P>Hypoglycaemia rates were reported in some detail in six studies comparing a single daily injection of insulin applied in the evening (<LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>; <LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK>; <LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK>; <LINK REF="STD-Riddle-1998" TYPE="STUDY">Riddle 1998</LINK>; <LINK REF="STD-Shank-1995" TYPE="STUDY">Shank 1995</LINK>; <LINK REF="STD-Sun-1995" TYPE="STUDY">Sun 1995</LINK>) to a matching insulin injection plus oral hypoglycaemic agents. No episodes of severe hypoglycaemia (requiring third party help) occurred. <LINK REF="STD-Riddle-1998" TYPE="STUDY">Riddle 1998</LINK> reported more frequent symptoms compatible with hypoglycaemia (though not confirmed biochemically) with combination therapy (51% of patients) compared to insulin monotherapy (37%) (P &lt; 0.05), though the quicker rate of decline of HbA1c seen in the combination therapy group was considered an important factor by trial investigators. Non-statistically significant increases in hypoglycaemia with combination therapy were reported in two studies (<LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK> ((mean ± SD) 8.8 ± 6.6 versus 6.9 ± 6.6 symptomatic hypoglycaemic events per patient), <LINK REF="STD-Shank-1995" TYPE="STUDY">Shank 1995</LINK> (0.1 ± 0.2 versus 0.2 ± 0.3 hypoglycaemic episodes (blood glucose less than 3.89 mmol/l) per patient per week. <LINK REF="STD-Sun-1995" TYPE="STUDY">Sun 1995</LINK> reported one subject experiencing hypoglycaemic symptoms in each of the monotherapy and combination therapy groups. <LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK> qualitatively reported similar rates of hypoglycaemia for both regimens. <LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK> reported a non-significant similar frequency of hypoglycaemia "sufficient to interrupt normal daily activities", occurring in six (40%) of patients on once daily basal insulin and five (33%) of those treated with sulphonylurea plus insulin.</P>
<P>

</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Twice-daily insulin monotherapy regimens </HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Bedtime NPH insulin plus oral hypoglycaemic agents.</HEADING>
<P>Hypoglycaemia was reported in four studies with compared twice-daily insulin monotherapy to bedtime NPH insulin plus either sulphonylurea (1) (<LINK REF="STD-Wolffenbuttel-1996" TYPE="STUDY">Wolffenbuttel 1996</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>), metformin (2) (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>), or sulphonylurea plus metformin (3) (<LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Bedtime NPH insulin plus sulphonylurea</HEADING>
<P>
<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK> reported a similar frequency of symptomatic hypoglycaemic episodes over 12 months of therapy, affecting (mean ± SD) 3.4 ± 4.7 patients treated with combination therapy versus 3.9 ± 7.8 treated with insulin alone. Fasting hypoglycaemic episodes (self-monitored fasting glucose less than 3.5 mmol/l) were less common with twice daily insulin monotherapy (1.2% of fasting glucose readings) than with sulphonylurea plus bedtime insulin (2.2%) (P &lt; 0.05). <LINK REF="STD-Wolffenbuttel-1996" TYPE="STUDY">Wolffenbuttel 1996</LINK> reported only severe hypoglycaemia, which did not occur in either treatment arm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Bedtime NPH insulin plus metformin</HEADING>
<P>One trial (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>) reported significantly less symptomatic ((mean ± SD episodes per patient) 1.8 ± 1.7 versus 3.9 ± 7.8) hypoglycaemic episodes with insulin plus metformin compared to insulin alone (P &lt; 0.05). Biochemical fasting hypoglycaemic episodes (less than 3.5 mmol/l) were similar 1.1% versus 1.2 % of measurements for insulin plus metformin and insulin monotherapy respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Bedtime NPH insulin plus sulphonylurea and metformin</HEADING>
<P>Symptomatic hypoglycaemia rates were similar in three studies comparing twice daily insulin monotherapy to regimens with sulphonylurea plus metformin plus bedtime NPH insulin; <LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK> (mean ± SD hypoglycaemic events per patient): 1.4 versus 1.0; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>: 4.0 ± 5.5 versus 1.0 ± 5.3; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>: 3.9 ± 7.8 versus 3.3 ± 7.7, for monotherapy versus combination therapy respectively (non-significant for each comparison). The frequency of low blood capillary glucose measurements was reported to be similar in one study (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK> (less than 4.0 mmol/l), though <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK> reported significantly more fasting hypoglycaemia (less than 3.5 mmol/l) with combination therapy compared to insulin monotherapy (1.8% versus 1.2% respectively, for all fasting glucose measurements (P &lt; 0.01).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Morning NPH plus sulphonylurea</HEADING>
<P>
<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK> reported non-significant similar rates of symptomatic hypoglycaemic events with monotherapy and combination therapy (mean ± SD per patient) 4 ± 5.5 versus 3 ± 5.7 respectively . <LINK REF="STD-Wolffenbuttel-1996" TYPE="STUDY">Wolffenbuttel 1996</LINK> reported a non-significant frequency of severe hypoglycaemia (requiring third party help), which over the study duration affected only one individual in the combination therapy group.</P>
<P/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Twice-daily insulin plus sulphonylurea</HEADING>
<P>
<LINK REF="STD-Bachmann-1988" TYPE="STUDY">Bachmann 1988</LINK> reported similar hypoglycaemia rates with both regimens (17% versus 20% of patients affected respectively (non-significant).<BR/>
<LINK REF="STD-Gutniak-1987" TYPE="STUDY">Gutniak 1987</LINK> reported more patients experiencing hypoglycaemia (glucose less than 3.5 mmol/l) with combination therapy than monotherapy in the first two weeks of the study (8.8% versus 4.1%, P &lt; 0.002) though hypoglycaemia rates declined during the course of the study to 1.2% and 2.6% per week at three months (non-significant between groups). Overall hypoglycaemia rates for the entire study were not reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">

</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Multiple-daily insulin injections </HEADING>
<P>Three studies comparing a multiple insulin injection regimen (pre-meal soluble insulin with bedtime NPH) with bedtime NPH insulin plus sulphonylurea (<LINK REF="STD-Bastyr-1999" TYPE="STUDY">Bastyr 1999</LINK>; <LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>) or sulphonylurea plus metformin (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>) reported frequency of hypoglycaemia.</P>
<P>Symptomatic (<LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>) and biochemical (<LINK REF="STD-Bastyr-1999" TYPE="STUDY">Bastyr 1999</LINK> (blood glucose &lt; 3.0 mmol/l) hypoglycaemia was non-significantly less with combination therapy in all three studies; <LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>: 33% versus 47% of patients affected; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>: (mean ± SD) 1 ± 5.3 versus 2 ± 5.6 episodes per patient; <LINK REF="STD-Bastyr-1999" TYPE="STUDY">Bastyr 1999</LINK>: 0.9 ± 2.3 versus 1.2 ± 2.4 events per patient per 30 days, for combination therapy and insulin monotherapy respectively (non-significant for each comparison).</P>
<P>
<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK> reported a similar frequency of biochemical hypoglycaemia (&lt; 4.0 mmol/l) with both regimens. <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK> also compared the same multiple injection regimen to a combination of morning NPH insulin plus sulphonylurea. Symptomatic hypoglycaemia ((mean ± SD) 3 ± 5.7 versus 2 ± 5.6 episodes per patient, for monotherapy and combination therapy respectively) and self monitored glucose values &lt; 4.0 mmol/l were not significantly different between groups. No significant differences in 30-day hypoglycaemia rates were found by <LINK REF="STD-Bastyr-1999" TYPE="STUDY">Bastyr 1999</LINK> who compared a multiple insulin injection regimen with sulphonylurea plus pre-meal soluble insulin. Mean ± SD episodes of hypoglycaemia per patient per 30 days were 1.2 ± 2.4 versus 1.0 ± 1.7, respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4"/>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Insulin dose</HEADING>
<P>Insulin doses were titrated to predetermined glycaemic targets based on fasting (± post prandial) or diurnal mean glucose values in fourteen studies; median fasting glucose target was less than 7.0 mmol/l (range: less than 5.6 to less than 10.1 mmol/l) (<LINK REF="STD-Bachmann-1988" TYPE="STUDY">Bachmann 1988</LINK>; <LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK>; <LINK REF="STD-F_x00f6_v_x00e9_nyi-1997" TYPE="STUDY">Fövényi 1997</LINK>; <LINK REF="STD-Gutniak-1987" TYPE="STUDY">Gutniak 1987</LINK>; <LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK>; <LINK REF="STD-Lundershausen-1987" TYPE="STUDY">Lundershausen 1987</LINK>; <LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK>; <LINK REF="STD-Riddle-1998" TYPE="STUDY">Riddle 1998</LINK>; <LINK REF="STD-Shank-1995" TYPE="STUDY">Shank 1995</LINK>; <LINK REF="STD-Wolffenbuttel-1991" TYPE="STUDY">Wolffenbuttel 1991</LINK>; <LINK REF="STD-Wolffenbuttel-1996" TYPE="STUDY">Wolffenbuttel 1996</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>). Six studies did not formally report glucose targets to which insulin doses were titrated (<LINK REF="STD-Bastyr-1999" TYPE="STUDY">Bastyr 1999</LINK>; <LINK REF="STD-Lotz-1988" TYPE="STUDY">Lotz 1988</LINK>; <LINK REF="STD-Pontiroli-1990" TYPE="STUDY">Pontiroli 1990</LINK>; <LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK>; <LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK>; <LINK REF="STD-Sun-1995" TYPE="STUDY">Sun 1995</LINK>). Three studies utilised structured insulin titration algorithms based on self-measured fasting capillary glucose levels. <LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK> commenced insulin at 30 units/day and increased the dose weekly by 20 units for mean fasting capillary glucose more than 10 mmol/l, by 15 units for 7.8 to 10 mmol/l, by 10 units 6.7 to 7.8 mmol/l and by 5 units for mean capillary glucose 5.6 to 6.7 mmol/l. A reduction in insulin dose of 5 to 10 units was permitted for recurrent symptomatic or biochemical hypoglycaemia (less than 3.3 mmol/l). <LINK REF="STD-Riddle-1998" TYPE="STUDY">Riddle 1998</LINK> commenced insulin at 10 units/day and increased the dose weekly by 10 units until fasting glucose was less than 7.8 mmol/l for two consecutive days, then by 5 units weekly until fasting glucose was less than 6.7 mmol/l, aiming for a target fasting glucose 5.5 to 6.7 mmol/l. <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK> used a patient-led insulin self-titration titration regimen based on daily fasting glucose measurements. Starting insulin dose equalled capillary fasting glucose (mmol/l) and insulin doses were subsequently increased by 2 or 4 units, if three successive fasting glucose measurements were above 6 or 8 mmol/l, respectively. Three studies restricted the maximum dose of insulin in combination regimens using once daily NPH insulin. <LINK REF="STD-F_x00f6_v_x00e9_nyi-1997" TYPE="STUDY">Fövényi 1997</LINK> considered combination therapy unsuccessful if insulin requirements exceeded 40 units at bedtime, such patients were converted to twice daily insulin monotherapy. <LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK> limited the maximum daily dose of insulin for combination therapy and insulin monotherapy regimens to 26 and 84 units (or less than 1 unit/kg bodyweight) respectively. Furthermore, where the bedtime insulin dose exceeded 24 units, the insulin dose was apportioned between two daily injections. <LINK REF="STD-Lotz-1988" TYPE="STUDY">Lotz 1988</LINK> similarly limited the maximum dose of a single daily NPH insulin injection to 28 units.<BR/>Overall, insulin-oral hypoglycaemic agent combination therapy was associated with a weighted mean relative reduction in total daily insulin requirement of 46% (range: -5 to 74%) compared to insulin monotherapy.<BR/>Compared with a single daily insulin injection, regimens combining a sulphonylurea with a matched daily insulin injection were associated with a 29% relative reduction in total daily insulin dose. Compared with twice daily insulin, combination regimens with bedtime NPH insulin were associated with relative reductions of 57%, 29% and 64%, for sulphonylurea, metformin or both oral agents, respectively. Similarly, regimens combining morning NPH insulin with a sulphonylurea ± metformin, and regimens utilizing twice daily insulin with sulphonylurea, were associated with relative reductions in total daily insulin dose of 43%, and 42% respectively, compared to twice daily insulin monotherapy.<BR/>In comparison with multiple daily insulin injections, combination regimens were also associated with a relative reduction in daily insulin requirement of 48%.</P>
<SUBSECTION>
<HEADING LEVEL="4"/>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Well-being, quality of life and treatment satisfaction</HEADING>
<P>Two studies objectively assessed well-being, quality of life or treatment satisfaction. <LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK> used a visual analogue score (VAS) based, structured well-being questionnaire to assess subjective well-being and acceptability of insulin injections. Similar significant improvements in subjective well-being following the initiation of insulin therapy were noted with both insulin monotherapy and insulin-OHA combination therapy groups. However, significantly more patients in the combination therapy group wanted to continue insulin therapy at the end of the study (89% versus 76% for insulin monotherapy, P &lt; 0.0001). <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK> also assessed subjective well-being with questionnaires. Insulin therapy with all insulin treatment regimens was associated with significantly greater improvement in the subjective sense of well-being (74%, 84%, 100% and 86% for the multiple insulin injection, OHA + morning NPH, OHA + evening NPH and twice-daily insulin mixture groups respectively) compared to the control group (41% improvement)(P&lt;0.001).<BR/>
<LINK REF="STD-Wolffenbuttel-1991" TYPE="STUDY">Wolffenbuttel 1991</LINK> and <LINK REF="STD-Wolffenbuttel-1996" TYPE="STUDY">Wolffenbuttel 1996</LINK> qualitatively reported "improved well-being in nearly all patients", though methods for measuring well-being were not stated and no between-group comparisons were made.</P>
<SUBSECTION>
<HEADING LEVEL="4"/>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Weight gain</HEADING>
<P>Fifteen studies provided information on body weight outcomes (body weight or body mass index). Due to the heterogeneity of reported data and the absence of standard deviations of mean differences in most studies only the results of studies in three subgroups (Comparison 02.02.01, Comparison 02.02.03 and Comparison 02.03.01) were pooled statistically.</P>
<P/>
<SUBSECTION>
<HEADING LEVEL="5">Once-daily insulin monotherapy regimens </HEADING>
<P>Mean within-group change in weight from baseline was reported in four studies. <LINK REF="STD-Riddle-1992" TYPE="STUDY">Riddle 1992</LINK>; <LINK REF="STD-Riddle-1998" TYPE="STUDY">Riddle 1998</LINK>; <LINK REF="STD-Shank-1995" TYPE="STUDY">Shank 1995</LINK> each found a non-significant trend to greater weight gain with insulin-sulphonylurea combination therapy compared to evening insulin alone (3.3 versus 3.9 kg, 4 versus 4.3 kg, 0.6 versus 4.5 kg, insulin monotherapy versus combination therapy for each study, respectively). One cross-over study (<LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK>) reported significantly greater weight gain for patients when treated with insulin-OHA combination therapy (mean ± SD) 2.6 ± 1.8 kg) compared to insulin alone (0.6 ± 2.2 kg, P &lt; 0.01), though a significant confounding carry-over effect was observed, suggesting that the weight gain associated with each therapeutic intervention was affected by the order of treatment.<BR/>
<LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK> found no significant difference in weight between groups at the end of each treatment period. Four studies (<LINK REF="STD-Lundershausen-1987" TYPE="STUDY">Lundershausen 1987</LINK>; <LINK REF="STD-Pontiroli-1990" TYPE="STUDY">Pontiroli 1990</LINK>; <LINK REF="STD-Sun-1995" TYPE="STUDY">Sun 1995</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>) did not provide weight gain data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Twice-daily insulin monotherapy regimens</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Bedtime NPH insulin plus oral hypoglycaemic agents</HEADING>
<UL>
<LI>Bedtime NPH plus sulphonylurea (three comparisons) </LI>
</UL>
<P>Compared with insulin monotherapy, insulin-OHA combination therapy was associated with a non-significant (pooled weighted mean difference) 0.2 kg less weight gain (95% CI: -0.2 to 0.6; P=0.3) (<LINK REF="STD-F_x00f6_v_x00e9_nyi-1997" TYPE="STUDY">Fövényi 1997</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>). There was no statistically significant heterogeneity (I<SUP>2 </SUP>= 0%; P = 0.69). <LINK REF="STD-Wolffenbuttel-1996" TYPE="STUDY">Wolffenbuttel 1996</LINK> reported a non-significant mean weight gain of 4 kg and 4.4 kg for insulin monotherapy and insulin-OHA combination therapy, respectively.<BR/>
</P>
<UL>
<LI>Bedtime NPH plus metformin (one comparison)</LI>
</UL>
<P>Insulin-OHA combination therapy resulted in a significant mean 3.7 kg less weight gain compared to insulin monotherapy (P &lt; 0.01) (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>).<BR/>
</P>
<UL>
<LI>Bedtime NPH plus sulphonylurea and metformin (three comparisons) </LI>
</UL>
<P>Compared with insulin monotherapy, combination therapy was associated with a non-significant (pooled weighted mean difference) 1.5 kg less weight gain (95% CI: -0.1 to 3.2; P = 0.07). The test for heterogeneity was not significant (Chi<SUP>2 </SUP>= 4.69; P = 0.1), although I<SUP>2</SUP> test showed notable heterogeneity (I<SUP>2 </SUP>= 57.3%) (<LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>).</P>
<P/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Morning NPH insulin plus oral hypoglycaemic agents</HEADING>
<P>In one comparison, weight gain with insulin monotherapy was 0.4 kg less with monotherapy compared to combination therapy (P = 0.57) (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>). <LINK REF="STD-Wolffenbuttel-1991" TYPE="STUDY">Wolffenbuttel 1991</LINK> also reported similar weight gain with both regimens (mean weight gain 4.2 kg with monotherapy versus 3.9 kg with insulin/sulphonylurea (non significant). <LINK REF="STD-Lotz-1988" TYPE="STUDY">Lotz 1988</LINK> expressed weight data as percentage change in BROCA index, no significant between-group differences were found.</P>
<P/>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Twice-daily insulin plus oral hypoglycaemic agents</HEADING>
<P>
<LINK REF="STD-Gutniak-1987" TYPE="STUDY">Gutniak 1987</LINK> reported non-significantly greater weight gain with insulin-OHA combination therapy compared to insulin monotherapy. <LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK> reported similar significant increases in (median) bodyweight (expressed absolute change in BMI) with both therapies. Data from <LINK REF="STD-Bachmann-1988" TYPE="STUDY">Bachmann 1988</LINK> were disregarded since patients were withdrawn from this study if weight gain exceeded 3 kg.</P>
<P>

</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Multiple-daily insulin injections</HEADING>
<P>Compared with insulin monotherapy, insulin-OHA combination therapy (<LINK REF="STD-Bastyr-1999" TYPE="STUDY">Bastyr 1999</LINK>; <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK>) was associated with a significant (pooled weighted mean difference) 1.1 kg less weight gain (95% CI: 0.5 to 1.7; P&lt;0.001). <LINK REF="STD-Holman-1987" TYPE="STUDY">Holman 1987</LINK> reported similar weight gain with both therapies. <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1992" TYPE="STUDY">Yki-Järvinen 1992</LINK> also compared multiple-daily insulin injections to sulphonylurea plus metformin and morning NPH insulin. Weight gain was non-significantly less with combination therapy. <LINK REF="STD-Bastyr-1999" TYPE="STUDY">Bastyr 1999</LINK> reported non-significantly less weight gain with sulphonylurea combined with pre-meal soluble insulin compared to basal-bolus insulin therapy.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other adverse effects</HEADING>
<P>No studies assessed diabetes-related morbidity, mortality or total mortality, though two studies reported adverse events in some detail (<LINK REF="STD-Bastyr-1999" TYPE="STUDY">Bastyr 1999</LINK>; <LINK REF="STD-Riddle-1998" TYPE="STUDY">Riddle 1998</LINK>). These studies reported no significant differences in frequency, or severity, of adverse events with insulin or combination therapy regimens. Gastrointestinal symptoms were not reported as an outcome measure in any study, though in one study (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>), side effects of metformin (diarrhoea, metallic taste, abdominal discomfort) necessitated study discontinuation for four patients randomised to receive metformin in conjunction with insulin (3 of 24) or insulin and sulphonylurea (1 of 24 patients).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-28 13:36:52 +0100" MODIFIED_BY="Gudrun Paletta">
<P>This review was performed to assess the effects of insulin monotherapy compared with combinations of insulin with oral hypoglycaemic agents in patients with inadequate glycaemic control despite treatment with oral hypoglycaemic agents. Of 127 potentially relevant studies, 20 randomised clinical trials met the inclusion criteria for this review. These studies included a total of 1811 participants, and mean trial duration was 10 months. Participants had mean age of 59.8 years and mean known duration of diabetes of 9.6 years. Twenty-eight relevant comparisons were evaluated and categorised according to clinically relevant treatment schemes, based on both daily frequency and timing of insulin injections and class of oral hypoglycaemic agents used.</P>
<P>Significant clinical heterogeneity was observed in the inclusion criteria of individual studies with respect to oral hypoglycaemic agent(s) (and doses) used and the level of glycaemia required to determine oral agent failure (see table of included studies), reflecting a change in the use of oral hypoglycaemic agents over time, drug licensing regulations in different countries, and a more aggressive modern approach to the glycaemic management of type 2 diabetes.</P>
<P>Of the oral agents used in combination therapy regimens sulphonylureas were most frequently utilised (75% of all comparisons), then sulphonylurea with metformin (21%), and in one study (4%) a combination regimen of metformin with insulin was used.</P>
<P>Overall study quality was poor (mean score 2.6 of maximal 7 points), and only five studies had adequate concealment of allocation. Most studies (85%) had a follow-op time of less than one year, so the long-term effects on glycaemic control, diabetes-related complications, and other relevant outcomes are unclear. Except in one subcategory (comparison 02.01.01) statistically heterogeneity was low or moderate. The results of this review should be interpreted against the background of these limitations.</P>
<P>
<I>

</I>
</P>
<SUBSECTION>
<HEADING LEVEL="2">Glycaemic control </HEADING>
<P>Glycaemic control was the main outcome measure in all studies. Of thirteen studies (21 comparisons) sufficient data could be extracted to calculate pooled effects on glycaemic control. The four cross-over studies were not used for the analyses since phase-specific data were not available and wash-out periods were not used.</P>
<P>The results of this systematic review demonstrate no statistically significant benefits on glycaemic control with insulin monotherapy (two or more daily injections) versus oral hypoglycaemic agents combined with a single bedtime injection of neutral protamine Hagedorn (NPH) insulin, except for one study that included a combination therapy arm with insulin-metformin (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>). This study reported significantly better glycaemic control with insulin-metformin compared with other insulin-OHA combination regimens and also insulin monotherapy. Compared with insulin-sulphonylurea, insulin-metformin combination therapy resulted in a significantly greater improvement in HbA1c of 0.6% (-1.9±1.4 versus -2.5±1.7, P&lt;0.05). This is also of clinical significance in light of the UKPDS (<LINK REF="REF-UKPDS-33" TYPE="REFERENCE">UKPDS 33</LINK>) which, with a 0.9% difference in HbA1c between intensively-treated and conventionally-treated patients, reported a statistically significant relative risk reduction in microvascular disease of 25%. It should be noted however that in this study (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>), analysis was not as per intention-to-treat and only 19 of 24 (79%) patients randomised to receive insulin-metformin completed the study. Besides, the insulin saving effect of sulphonylurea was lost. Therefore the results of this study should be interpreted with caution.</P>
<P>Insulin-OHA combination therapy provided statistically significantly lower HbA1c (pooled difference of 0.3%) compared with insulin monotherapy when the latter was applied as a once-daily injection of NPH insulin. Conversely, twice-daily insulin monotherapy (NPH or mixed insulin) provided lower HbA1c (pooled difference 0.4%) to insulin-OHA combination therapy only if insulin was given as a single morning injection. Since these regimens are infrequently currently used in the management of type 2 diabetes, conclusions drawn from these results are limited. Besides, in both cases the weighted mean differences between the two insulin schemes were small and, although statistically significant, less clinically relevant.</P>
<P>These results do suggest that present-day combination therapy regimens provide at least comparable glycaemic control compared to insulin monotherapy. This is relevant for daily diabetes care, since the simple addition of bedtime NPH insulin to oral hypoglycaemic agents (metformin ± sulphonylurea) may allow physicians and patients to overcome a possible resistance to the use of insulin. Moreover, from a clinical standpoint the beneficial insulin sparing effects of oral agents could be maintained. In this respect the continuation of sulphonylurea is more beneficial than the continuation of metformin. Opponents to bedtime NPH insulin-OHA combination therapy suggest that glycaemic control remains sub-optimal with this approach (<LINK REF="REF-Westphal-2003" TYPE="REFERENCE">Westphal 2003</LINK>), however, the results of this review demonstrate that insulin monotherapy fares no better with respect to glycaemic control. This is of particular relevance to elderly patients where the inherent risk of hypoglycaemia may outweigh the benefits of tight glycaemic control.</P>
<P>
<I>

</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Quality of life </HEADING>
<P>Quality of life related issues were investigated in only four studies, so this review could not be conclusive regarding quality of life. In general, these studies reported improved well-being with both insulin monotherapy and insulin-OHA combination regimens, with no significant differences between groups.</P>
<P>
<I>

</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Insulin dose </HEADING>
<P>In seventy percent of the studies insulin doses were titrated to predetermined glycaemic targets based on fasting or diurnal mean glucose values (median fasting glucose target less than 7.0 mmol/l; range 5.6 to 10.1 mmol/L). In less than half (45%) of the studies were patients instructed to measure blood glucose levels at home. Three studies restricted the maximum dose of insulin in combination regimens using once-daily NPH insulin (range 26 to 40 IU). Overall, insulin-OHA combination therapy was associated with a relative reduction in total daily insulin requirement of 46% compared to insulin monotherapy (all schemes). This figure reflects the insulin saving capacity of oral hypoglycaemic agents when combined with insulin. However, compared with twice-daily or multiple injection monotherapy regimens, the insulin-sparing effect of a sulphonylurea whether or not combined with metformin seemed to be superior to that of metformin alone (~50% versus 29%), although the latter figure was based on data from a solitary study (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>).</P>
<P>
<I>

</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Hypoglycaemia</HEADING>
<P>Hypoglycaemia was reported quantitatively or qualitatively in all but five studies (<LINK REF="STD-F_x00f6_v_x00e9_nyi-1997" TYPE="STUDY">Fövényi 1997</LINK>; <LINK REF="STD-Lundershausen-1987" TYPE="STUDY">Lundershausen 1987</LINK>; <LINK REF="STD-Pontiroli-1990" TYPE="STUDY">Pontiroli 1990</LINK>; <LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>) Heterogeneity in the definitions used between studies, and the quality of reporting of hypoglycaemia precluded the pooling of data. Of the fourteen studies (22 comparisons) that reported hypoglycaemia, all but one (comparison 02.01.02) (<LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK>) demonstrated no statistically significant difference in the frequency of hypoglycaemic events (symptomatic or biochemical) between insulin monotherapy and insulin-OHA combination therapy. Overall, only one episode of severe hypoglycaemia (requiring third party assistance) was reported (<LINK REF="STD-Wolffenbuttel-1996" TYPE="STUDY">Wolffenbuttel 1996</LINK>).</P>
<P>
<I>

</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Weight gain</HEADING>
<P>Of 10 studies (13 comparisons) sufficient data could be extracted to calculate pooled effects on body weight. Overall, the results of this review suggest that insulin-OHA combination therapy resulted in statistically significant less weight gain compared with insulin monotherapy provided that NPH insulin was applied at bedtime and metformin was used as a single agent or in combination with a sulphonylurea. In all other comparisons no significant differences with respect to weight gain were detected between monotherapy and combination therapy regimens. Metformin reduces insulin requirement and may also prevent weight gain, even in combination with a sulphonylurea or intensive insulin treatment. However, only one study included a treatment arm with insulin in combination with metformin alone. Whether metformin should be used as a single agent, or applied in conjunction with other oral agents in insulin combination regimens remains unclear.</P>
<P>
<I>

</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Adverse effects</HEADING>
<P>Very few studies in this review systematically reported adverse effects of oral agents or insulin in detail. Withdrawal of patients due to side-effects of oral medication (e.g. gastrointestinal symptoms of metformin use) appeared minimal.</P>
<P>
<I>

</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Limitations</HEADING>
<P>Overall, study quality was low (mean score 2.6 (range 0 to 7), and no study included a power calculation. The majority of studies had small sample size and limited follow-up and were therefore unable to report on hard end-points. Of the studies included in this review, combination regimens utilising oral hypoglycaemic agents with a single bedtime injection of NPH insulin provided comparable glycaemic control to any insulin monotherapy regimen, though the long-term success of such regimens remains unclear.</P>
<P>
<LINK REF="STD-Wolffenbuttel-1996" TYPE="STUDY">Wolffenbuttel 1996</LINK> reported that after six months of treatment, 32% of patients in the sulphonylurea-bedtime neutral protamine Hagedorn (NPH) insulin arm required a second injection at morning time to control glycaemia. Similarly, <LINK REF="STD-F_x00f6_v_x00e9_nyi-1997" TYPE="STUDY">Fövényi 1997</LINK> reported that 40.5% of patients at 12 months, and 58.2% of patients at three years, required conversion to conventional insulin therapy because of inadequate glycaemic control, though combination therapy was considered unsuccessful if the dose of bedtime NPH insulin required to suppress fasting glucose to less than 7.0 mmol/L exceeded 40 units. <LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK> divided the bedtime insulin between two daily injections when the total daily insulin requirement exceeded 24 units. <LINK REF="STD-Yki_x002d_J_x00e4_rvinen-1999" TYPE="STUDY">Yki-Järvinen 1999</LINK> however, using a patient led structured insulin dose titration regimen targeting fasting glycaemia, reported that individual bedtime NPH insulin dose required to achieve fasting glucose values less than 6.0 mmol/L ranged from 8 to 168 units, suggesting that some patients in other studies may have been unnecessarily converted to conventional insulin regimens. This regimen was associated with a low drop-out rate; over one year of treatment no patients withdrew due to lack of efficacy of treatment.</P>
<P>Three studies attempted to identify criteria that predicted a good response to combination therapy. <LINK REF="STD-Ravnik_x002d_Oblak-1995" TYPE="STUDY">Ravnik-Oblak 1995</LINK> reported that those who responded well to combination therapy had a shorter duration of diabetes, greater bodyweight and a higher basal C-peptide at baseline, to those who responded poorly. However, age, diabetes duration, BMI, glycaemia, peripheral insulin resistance or ß-cell insulin secretory capacity were not useful predictors. <LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK> and <LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK> also found no correlation between these baseline values and future success of combination therapy, in addition to prior oral hypoglycaemic therapy and initial lipid sub-fractions.</P>
<P>No published studies have directly compared bedtime insulin regimens with oral hypoglycaemic agents combined with long-acting insulin analogues to insulin monotherapy, although two large studies (<LINK REF="REF-Riddle-2003" TYPE="REFERENCE">Riddle 2003</LINK> (n = 756); <LINK REF="REF-Yki_x002d_J_x00e4_rvinen-2000" TYPE="REFERENCE">Yki-Järvinen 2000</LINK> (n = 426)) have compared combination regimens with oral hypoglycaemic agents and bedtime NPH insulin versus insulin glargine over 24 and 52 weeks respectively. In both studies, similar levels of glycaemic control were achieved with both regimens, though with significantly less nocturnal hypoglycaemia with insulin glargine. Using a forced insulin titration regimen, <LINK REF="REF-Riddle-2003" TYPE="REFERENCE">Riddle 2003</LINK> systematically titrated insulin doses on a weekly basis to achieve fasting plasma glucose levels of less than 5.5 mmol/L. Both regimens achieved a mean HbA1c at 24 weeks of less than 7.0% (6.96% (glargine) versus 6.97% (NPH), reference range 4 to 6%).</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-10-22 11:11:37 +0200" MODIFIED_BY="Gudrun Paletta">
<IMPLICATIONS_PRACTICE MODIFIED="2008-10-03 17:22:37 +0200" MODIFIED_BY="[Empty name]">
<P>MI, glycaemia, peripheral insulin resistance or ß-cell insulin secretory capacity were not useful predictors. <LINK REF="STD-Chow-1995" TYPE="STUDY">Chow 1995</LINK> and <LINK REF="STD-Riddle-1989" TYPE="STUDY">Riddle 1989</LINK> also found no correlation between these baseline values and future success of combination therapy, in addition to prior oral hypoglycaemic therapy and initial lipid sub-fractions.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-10-22 11:11:37 +0200" MODIFIED_BY="Gudrun Paletta">
<P>More studies are required to determine the optimal combination of antidiabetic agents for this category of patients. These studies should focus on hard endpoints as (diabetes-related) morbidity and mortality, treatment satisfaction, quality of life and general well-beingincluding, and safety aspects of the different combination regimens (e.g. sulphonylureas and metformin), should be larger with respect to number of patients, and have longer follow-up. These studies should also include newer oral agents (e.g. meglitinides, thiazolidinediones). Further research on this issue should assess also the possible long-term benefits over NPH insulin of recently introduced long-acting insulin analogues (<LINK REF="REF-Riddle-2003" TYPE="REFERENCE">Riddle 2003</LINK>).</P>
<P>Further research should address the following questions:<BR/>
</P>
<UL>
<LI>Is insulin-OHA combination therapy with metformin preferable to sulphonylurea plus metformin?</LI>
<LI>Is there a ceiling effect for insulin dose in insulin-OHA combination therapy, above which there is little / no benefit?</LI>
<LI>Can failure on insulin-OHA combination therapy be predicted from patient characteristics at baseline?</LI>
<LI>What are the effects of long-acting insulin analogues (glargine, detemir) versus NPH insulin when combined with oral hypoglycaemic agents?</LI>
<LI>What insulin schemes are preferred by patients, and do they affect quality of life and general well-being?</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank the authors Francis Chow, József Fövényi, Rury Holman, and Antonio Pontiroli who kindly provided unpublished information.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>In 1999 ANG has received an unrestricted research grant from Novo Nordisk for conducting studies on monitoring and treatment of patients with type 2 diabetes in primary care.<BR/>Research conducted by NJF during 1999-2001 was supported by an unrestricted research grant from Novo Nordisk. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>AN GOUDSWAARD: Protocol development, searching for trials, trial selection, quality assessment of trials, data extraction, review development.</P>
<P>NJ FURLONG: Quality assessment of trials, data extraction, review development.</P>
<P>GD VALK: Protocol development, trial selection, quality assessment of trials, data extraction, review development.</P>
<P>RP STOLK: Methodology, statistics.</P>
<P>GEHM RUTTEN: Review development.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-03 17:21:45 +0200" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bachmann-1988" NAME="Bachmann 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;0012-0472&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bachmann W, Lotz N, Mehnert H, Rosak C, Schoffling K</AU>
<TI>[Effectiveness of combined treatment with glibenclamide and insulin in secondary sulfonylurea failure. A controlled multicenter double-blind clinical trial]</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1988</YR>
<VL>113</VL>
<NO>16</NO>
<PG>631-36</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3832"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bastyr-1999" NAME="Bastyr 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bastyr EJ, Johnson ME, Trautmann ME, Anderson JH, Vignati L</AU>
<TI>Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure</TI>
<SO>Clinical Therapeutics</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>10</NO>
<PG>1703-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Chow-1995" NAME="Chow 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chow CC, Tsang LW, Sorensen JP, Cockram CS</AU>
<TI>Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients</TI>
<SO>Diabetes Care</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>3</NO>
<PG>307-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-F_x00f6_v_x00e9_nyi-1997" NAME="Fövényi 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fövényi J, Grosz A, Thaisz E, Lehotkai, L, Sallai T, Kocsis G</AU>
<TI>[Daytime sulfonyluyrea - bedtime insulin combination therapy in Type II diabetes]</TI>
<SO>Magy Belorv Arch (Hungarian Archive of Internal Medicine)</SO>
<YR>1997</YR>
<VL>50</VL>
<PG>607-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gutniak-1987" NAME="Gutniak 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gutniak M, Karlander SG, Efendic S</AU>
<TI>Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea</TI>
<SO>Diabetes Care</SO>
<YR>1987</YR>
<VL>10</VL>
<NO>5</NO>
<PG>545-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holman-1987" NAME="Holman 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holman RR, Steemson J, Turner RC</AU>
<TI>Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement</TI>
<SO>Diabetic Medicine</SO>
<YR>1987</YR>
<VL>4</VL>
<NO>5</NO>
<PG>457-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karlander-1991" NAME="Karlander 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karlander SG, Gutniak MK, Efendic S</AU>
<TI>Effects of combination therapy with glyburide and insulin on serum lipid levels in NIDDM patients with secondary sulfonylurea failure</TI>
<SO>Diabetes Care</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>11</NO>
<PG>963-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lotz-1988" NAME="Lotz 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lotz N, Bachmann W, Ladik T, Mehnert H</AU>
<TI>[Combination therapy with insulin/sulfonylurea in the long-term therapy of type II diabetes following "secondary failure"]. [German]</TI>
<SO>Klinische Wochenschrift</SO>
<YR>1988</YR>
<VL>66</VL>
<NO>21</NO>
<PG>1079-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundershausen-1987" NAME="Lundershausen 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lundershausen R, Orban S, Pissarek D, Panzram G</AU>
<TI>[Long-term effect of combination glibenclamide-insulin treatment in the secondary failure of sulfonylurea therapy--results of a one-year double blind study]. [German]</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1987</YR>
<VL>99</VL>
<NO>17</NO>
<PG>603-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00e4_kimattila-1999" NAME="Mäkimattila 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mäkimattila S, Nikkila K, Yki-Järvinen H</AU>
<TI>Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus</TI>
<SO>Diabetologia</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>4</NO>
<PG>406-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pontiroli-1990" NAME="Pontiroli 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pontiroli AE, Dino G, Capra F, Pozza G</AU>
<TI>Combined therapy with glibenclamide and ultralente insulin in lean patients with NIDDM with secondary failure of sulfonylureas. Follow up at two years</TI>
<SO>Diabete et Metabolisme</SO>
<YR>1990</YR>
<VL>16</VL>
<NO>4</NO>
<PG>323-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ravnik_x002d_Oblak-1995" NAME="Ravnik-Oblak 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ravnik-Oblak M, Mrevlje F</AU>
<TI>Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure</TI>
<SO>Diabetes Research &amp; Clinical Practice</SO>
<YR>1995</YR>
<VL>30</VL>
<NO>1</NO>
<PG>27-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riddle-1989" NAME="Riddle 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;UI - 90004808&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riddle MC, Hart JS, Bouma DJ, Phillipson BE, Youker G</AU>
<TI>Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects</TI>
<SO>Diabetes Care</SO>
<YR>1989</YR>
<VL>12</VL>
<NO>9</NO>
<PG>623-29</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riddle-1992" NAME="Riddle 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riddle M, Hart J, Bingham P, Garrison C, McDaniel P</AU>
<TI>Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea</TI>
<SO>American Journal of the Medical Sciences</SO>
<YR>1992</YR>
<VL>303</VL>
<NO>3</NO>
<PG>151-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riddle-1998" NAME="Riddle 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riddle MC, Schneider J</AU>
<TI>Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>7</NO>
<PG>1052-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shank-1995" NAME="Shank 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shank ML, Del Prato S, DeFronzo RA</AU>
<TI>Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM</TI>
<SO>Diabetes</SO>
<YR>1995</YR>
<VL>44</VL>
<PG>165-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-1995" NAME="Sun 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun Y, Xiong Y, Yang J</AU>
<TI>[The effectiveness of combined insulin and sulfonylurea in treating non-insulin dependent diabetic patients]. [Chinese]</TI>
<SO>Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine</SO>
<YR>1995</YR>
<VL>34</VL>
<NO>4</NO>
<PG>246-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolffenbuttel-1991" NAME="Wolffenbuttel 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolffenbuttel BH, Rondas-Colbers GJ, Menheere PP, Sels JP, Nieuwenhuijzen-Kruseman AC</AU>
<TI>[The effects of insulin combined with glibenclamide on glucose and lipid metabolism in patients with Type II diabetes mellitus]</TI>
<SO>Ned Tijdschr Geneeskd</SO>
<YR>1991</YR>
<VL>135</VL>
<PG>1080-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolffenbuttel-1996" NAME="Wolffenbuttel 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ, Menheere PP, Nieuwenhuijzen-Kruseman AC</AU>
<TI>Comparison of different insulin regimens in elderly patients with NIDDM</TI>
<SO>Diabetes Care</SO>
<YR>1996</YR>
<VL>19</VL>
<PG>1326-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2001" NAME="Xu 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu WC, Chen CR, Chen YS</AU>
<TI>Combination therapy with bedtime insulin and daytime oral hypoglycaemic agents in type 2 diabetic patients [Chinese]</TI>
<SO>Hebei Medicine</SO>
<YR>2001</YR>
<VL>23</VL>
<PG>23-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7231"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yki_x002d_J_x00e4_rvinen-1992" NAME="Yki-Järvinen 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al</AU>
<TI>Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>327</VL>
<NO>20</NO>
<PG>1426-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yki_x002d_J_x00e4_rvinen-1999" NAME="Yki-Järvinen 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yki-Järvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M</AU>
<TI>Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1999</YR>
<VL>130</VL>
<NO>5</NO>
<PG>389-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-1985" NAME="Allen 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen BT, Feinglos MN, Lebovitz HE</AU>
<TI>Treatment of poorly regulated non-insulin-dependent diabetes mellitus with combination insulin-sulfonylurea</TI>
<SO>Arch Intern Med</SO>
<YR>1985</YR>
<VL>145</VL>
<NO>10</NO>
<PG>1900-03</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aviles-1999" NAME="Aviles 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aviles-Santa L, Sinding J, Raskin P</AU>
<TI>Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1999</YR>
<VL>131</VL>
<NO>3</NO>
<PG>182-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bastyr-2000" NAME="Bastyr 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, et al</AU>
<TI>Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. [see comments]</TI>
<SO>Diabetes Care</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>9</NO>
<PG>1236-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bieger-1984" NAME="Bieger 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bieger WP, Dlugosch R, Rettenmeier A, Holler HD, Bert H, Schwarz W, et al</AU>
<TI>Trial of sulfonylurea in combination with insulin in the therapy of diabetes type I and II. Evidence against a primary extrapancreatic receptor effect</TI>
<SO>Klinische Wochenschrift</SO>
<YR>1984</YR>
<VL>62</VL>
<NO>13</NO>
<PG>631-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Birkeland-1994" NAME="Birkeland 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Birkeland KI, Hanssen KF, Urdal P, Berg K, Vaaler S</AU>
<TI>A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes [see comments]</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1994</YR>
<VL>236</VL>
<PG>305-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Birkeland-1996" NAME="Birkeland 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Birkeland KI, Rishaug U, Hanssen KF, Vaaler S</AU>
<TI>NIDDM: a rapid progressive disease. Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment</TI>
<SO>Diabetologia</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>1629-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruns-1988" NAME="Bruns 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruns W, Willkommen G, Philipp A, Czeczatka W, Hildebrandt R, Jutzi E</AU>
<TI>Zur Behandlung von Typ II (non-insulin-dependent)-Diabetikern mit Sulfonylharnstoff-Sekundärversagen Kombinationstherapie von Glibenclamid und Insulin</TI>
<SO>Zeitschrift für Klinische Medizin</SO>
<YR>1988</YR>
<VL>43</VL>
<PG>625-29</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7232"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calle-1995" NAME="Calle 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calle-Pascual AL, Garcia HJ, Martin-Alvarez PJ, Vara E, Calle JR, Munguira ME, et al</AU>
<TI>Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment</TI>
<SO>Diabetes and Metabolism</SO>
<YR>1995</YR>
<VL>21</VL>
<PG>256-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Camerini-1994" NAME="Camerini 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Camerini-Davalos RA BJJV</AU>
<TI>Effect of insulin-glipizide combination on skeletal muscle capillary basement membrane width in diabetic patients</TI>
<SO>Clinical Therapeutics</SO>
<YR>1994</YR>
<VL>16</VL>
<NO>6</NO>
<PG>952-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carta-1984" NAME="Carta 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carta Q, Trovati M, Dani F, Caselle MT, Vitali S, Cavalot F, et al</AU>
<TI>[Insulin or insulin + oral hypoglycemic drugs in the treatment of type 2 diabetes difficult to compensate metabolically?]. [Italian]</TI>
<SO>Minerva Endocrinologica</SO>
<YR>1984</YR>
<VL>9</VL>
<NO>2</NO>
<PG>241-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casner-1988" NAME="Casner 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casner PR</AU>
<TI>Insulin-glyburide combination therapy for non-insulin-dependent diabetes mellitus: a long-term double-blind, placebo-controlled trial</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>1988</YR>
<VL>44</VL>
<NO>5</NO>
<PG>594-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castillo-1987" NAME="Castillo 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castillo M, Scheen AJ, Paolisso G, Lefebvre PJ</AU>
<TI>The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion</TI>
<SO>Acta Endocrinologica</SO>
<YR>1987</YR>
<VL>116</VL>
<NO>3</NO>
<PG>364-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chazan-2001" NAME="Chazan 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chazan AC, Gomes MB</AU>
<TI>Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure</TI>
<SO>Brazilian Journal of Medical &amp; Biological Research</SO>
<YR>2001</YR>
<VL>34</VL>
<NO>1</NO>
<PG>49-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiasson-1994" NAME="Chiasson 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;UI - 95069413&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA,</AU>
<TI>The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>121</VL>
<NO>12</NO>
<PG>928-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="27"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clauson-1996" NAME="Clauson 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clauson P, Karlander S, Steen L, Efendic S</AU>
<TI>Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up</TI>
<SO>Diabetic Medicine</SO>
<YR>1996</YR>
<VL>13</VL>
<NO>5</NO>
<PG>471-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cortes-1993" NAME="Cortes 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cortes AH, Espinosa Lopez FR, Angulo Cervera JA, Diaz TJ</AU>
<TI>[A comparative study of insulin and glyburide versus glyburide or insulin in the chronic control of patients with type-2 diabetes]. [Spanish]</TI>
<SO>Gaceta Medica de Mexico</SO>
<YR>1993</YR>
<VL>129</VL>
<NO>6</NO>
<PG>383-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diehl-1985" NAME="Diehl 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diehl AK, Sugarek NJ, Bauer RL</AU>
<TI>Medication compliance in non-insulin-dependent diabetes: a randomized comparison of chlorpropamide and insulin</TI>
<SO>Diabetes Care</SO>
<YR>1985</YR>
<VL>8</VL>
<PG>219-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elgrably-1991" NAME="Elgrably 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;UI - 92136787&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elgrably F, Costagliola D, Chwalow AJ, Varenne P, Slama G, Tchobroutsky G</AU>
<TI>Initiation of insulin treatment after 70 years of age: patient status 2 years later</TI>
<SO>Diabet Med</SO>
<YR>1991</YR>
<VL>8</VL>
<NO>8</NO>
<PG>773-77</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3682"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falko-1985" NAME="Falko 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falko JM, Osei K</AU>
<TI>Combination insulin/glyburide therapy in type II diabetes mellitus. Effects on lipoprotein metabolism and glucoregulation</TI>
<SO>American Journal of Medicine</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>3B</NO>
<PG>92-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feinglos-1997" NAME="Feinglos 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD</AU>
<TI>Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>10</NO>
<PG>1539-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feinglos-1998" NAME="Feinglos 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feinglos MN, Thacker CR, Lobaugh B, DeAtkine DD, McNeill DB, English JS,</AU>
<TI>Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus</TI>
<SO>Diabetes Research &amp; Clinical Practice</SO>
<YR>1998</YR>
<VL>39</VL>
<NO>3</NO>
<PG>193-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Firth-1986" NAME="Firth 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Firth RG, Bell PM, Rizza RA</AU>
<TI>Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1986</YR>
<VL>314</VL>
<PG>1280-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Firth-1987" NAME="Firth 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Firth R, Bell P, Marsh M, Rizza RA</AU>
<TI>Effects of tolazamide and exogenous insulin on pattern of postprandial carbohydrate metabolism in patients with non-insulin- dependent diabetes mellitus. Results of randomized crossover trial</TI>
<SO>Diabetes</SO>
<YR>1987</YR>
<VL>36</VL>
<PG>1130-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fonseca-2000" NAME="Fonseca 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;UI - 20324717&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fonseca V, Foyt HL, Shen K, Whitcomb R</AU>
<TI>Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients</TI>
<SO>Diabetes Care</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>3</NO>
<PG>354-59</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7231"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fritsche-2000" NAME="Fritsche 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fritsche A, Schmulling RM, Haring HU, Stumvoll M</AU>
<TI>Intensive insulin therapy combined with metformin in obese type 2 diabetic patients</TI>
<SO>Acta Diabetologica</SO>
<YR>2000</YR>
<VL>37</VL>
<NO>1</NO>
<PG>13-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giugliano-1993" NAME="Giugliano 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Department of Geriatrics and Metabolic Diseases, First Faculty of Medicine, University of Naples, Italy The efficacy and safety of metformin in the treatment of obese, non-insulin-dependent, diabetic subjects poorly controlled by insulin after secondary failure to respond to sulphonylureas has been investigated. Fifty insulin-treated, obese diabetics participated in this prospective, randomised double-blind six- month trial. After a four-week run-in period, during which all patients were given placebo (single-blind), patients were randomly assigned to continue to receive placebo or to active treatment with metformin. At six months, there was a relevant and significant improvement in glycaemic control in diabetics receiving the combined insulin-metformin treatment (decrease in glucose -4.1 mmol.l-1; glycosylated haemoglobin A1 decrease - 1.84%). No significant changes were seen in diabetics receiving insulin and placebo. There was a significant decrease in blood lipids (trygliceride and cholesterol), an increase in HDL- cholesterol and a reduction in blood pressure in diabetics taking metformin. These positive findings were most marked in the 14 diabetics who experienced a good response to metformin (glucose profile &amp;lt; 10 mmol.l-1), and were less marked but still significant in the remaining 13 diabetics, whose response to therapy was not so good (glucose profile &amp;gt; 10 mmol.l-1). The fasting insulin level was significantly lower after six months of combined insulin-metformin treatment as shown by a 25% reduction in the daily dose of insulin (-21.6 U/day). Metformin was well tolerated by all diabetics.(ABSTRACT TRUNCATED AT 250 WORDS) Clinical Trial. Journal Article. Randomized Controlled Trial&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, et al</AU>
<TI>Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1993</YR>
<VL>44</VL>
<NO>2</NO>
<PG>107-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4664"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groop-1984" NAME="Groop 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groop L, Harno K, Tolppanen EM</AU>
<TI>The combination of insulin and sulphonylurea in the treatment of secondary drug failure in patients with type II diabetes</TI>
<SO>Acta Endocrinologica</SO>
<YR>1984</YR>
<VL>106</VL>
<NO>1</NO>
<PG>97-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groop-1985" NAME="Groop 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groop L, Harno K, Nikkila EA, Pelkonen R, Tolppanen EM</AU>
<TI>Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1985</YR>
<VL>217</VL>
<NO>1</NO>
<PG>33-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groop-1989" NAME="Groop 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groop L, Widen E, Franssila-Kallunki A, Ekstrand A, Saloranta C, Schalin, C, et al</AU>
<TI>Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus</TI>
<SO>Diabetologia</SO>
<YR>1989</YR>
<VL>32</VL>
<NO>8</NO>
<PG>599-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groop-1991" NAME="Groop 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groop L, Widen E</AU>
<TI>Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy?</TI>
<SO>Diabete et Metabolisme</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>1 Pt 2</NO>
<PG>218-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groop-1992" NAME="Groop 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groop LC, Widen E, Ekstrand A, Saloranta C, Franssila-Kallunki A, Schalin-Jantti C, et al</AU>
<TI>Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM</TI>
<SO>Diabetes Care</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>7</NO>
<PG>831-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guvener-1999" NAME="Guvener 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guvener N, Gedik O</AU>
<TI>Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients</TI>
<SO>Acta Diabetologica</SO>
<YR>1999</YR>
<VL>36</VL>
<NO>1-2</NO>
<PG>93-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamelbeck-1982" NAME="Hamelbeck 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;UI - 83026963&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamelbeck H, Klein W, Zoltobrocki M, Schoffling K</AU>
<TI>[Glibenclamide-insulin combination in the management of secondary failure of sulfonyl-urea medication]</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1982</YR>
<VL>107</VL>
<NO>42</NO>
<PG>1581-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7230"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hirsch-1999" NAME="Hirsch 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hirsch IB</AU>
<TI>Metformin added to insulin therapy in poorly controlled type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>5</NO>
<PG>854</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Josse-1995" NAME="Josse 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Josse RG</AU>
<TI>Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial. [erratum appears in Diabetes Res Clin Pract 1995 Sep;29(3):215]</TI>
<SO>Diabetes Research &amp; Clinical Practice</SO>
<YR>1995</YR>
<VL>28 Suppl</VL>
<PG>S167-S172</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasim-1986" NAME="Kasim 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasim SE, LeBoeuf RC, Rockett MJ, Page J, Keyser AJ</AU>
<TI>The effects of oral agent or insulin treatments on the plasma lipoproteins and the plasma lipoprotein lipase activator in diabetic patients</TI>
<SO>Hormone &amp; Metabolic Research</SO>
<YR>1986</YR>
<VL>18</VL>
<NO>3</NO>
<PG>190-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelley-1998" NAME="Kelley 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;UI - 99056473&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, et al</AU>
<TI>Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>12</NO>
<PG>2056-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="49"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kitabchi-1987" NAME="Kitabchi 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kitabchi AE, Soria AG, Radparvar A, Lawson-Grant V</AU>
<TI>Combined therapy of insulin and tolazamide decreases insulin requirement and serum triglycerides in obese patients with noninsulin-dependent diabetes mellitus</TI>
<SO>American Journal of the Medical Sciences</SO>
<YR>1987</YR>
<VL>294</VL>
<NO>1</NO>
<PG>10-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-1991" NAME="Klein 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein W</AU>
<TI>Sulfonylurea-metformin-combination&lt; /strong&gt; versus sulfonylurea-insulin-combination&lt;/s trong&gt; in secondary failures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients</TI>
<SO>Diabete et Metabolisme</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>1 Pt 2</NO>
<PG>235-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kyllastinen-1985" NAME="Kyllastinen 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kyllastinen M, Groop L</AU>
<TI>Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients</TI>
<SO>Annals of Clinical Research</SO>
<YR>1985</YR>
<VL>17</VL>
<NO>3</NO>
<PG>100-04</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Landstedt-1995" NAME="Landstedt 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landstedt-Hallin L, Adamson U, Arner P, Bolinder J, Lins PE</AU>
<TI>Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure</TI>
<SO>Diabetes Care</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>8</NO>
<PG>1183-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="38"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Landstedt-1999" NAME="Landstedt 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landstedt-Hallin L, Arner P, Lins PE, Bolinder J, Olsen H, Groop L</AU>
<TI>The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal. Scandinavian Insulin-Sulphonylurea Study Group Research Team</TI>
<SO>Diabetic Medicine</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>10</NO>
<PG>827-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lardinois-1985" NAME="Lardinois 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lardinois CK, Liu GC, Reaven GM</AU>
<TI>Glyburide in non-insulin-dependent diabetes. Its therapeutic effect in patients with disease poorly controlled by insulin alone</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1985</YR>
<VL>145</VL>
<NO>6</NO>
<PG>1028-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lawrence-1988" NAME="Lawrence 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lawrence AM, Abraira C</AU>
<TI>New modalities in diabetes treatment</TI>
<SO>The American journal of medicine</SO>
<YR>1988</YR>
<VL>85</VL>
<PG>153-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lebovitz-1990" NAME="Lebovitz 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;UI - 90291874&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lebovitz HE, Pasmantier R</AU>
<TI>Combination insulin-sulfonylurea therapy</TI>
<SO>Diabetes Care</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>6</NO>
<PG>667-75</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6429"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewitt-1989" NAME="Lewitt 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewitt MS, Yu VK, Rennie GC, Carter JN, Marel GM, Yue DK, et al</AU>
<TI>Effects of combined insulin-sulfonylurea therapy in type II patients. [see comments]</TI>
<SO>Diabetes Care</SO>
<YR>1989</YR>
<VL>12</VL>
<NO>6</NO>
<PG>379-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liedtke-1990" NAME="Liedtke 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liedtke RK SMM</AU>
<TI>Transdermal insulin application in type II diabetic patients. Results of a clinical pilot study</TI>
<SO>Arzneimittel-Forschung Drug Research</SO>
<YR>1990</YR>
<VL>40</VL>
<NO>8</NO>
<PG>884-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindstrom-1992" NAME="Lindstrom 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindstrom T, Arnqvist HJ, Ludvigsson J, von Schenck HH</AU>
<TI>C-peptide profiles in patients with non-insulin-dependent diabetes mellitus before and during insulin treatment</TI>
<SO>Acta Endocrinologica</SO>
<YR>1992</YR>
<VL>126</VL>
<NO>6</NO>
<PG>477-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindstrom-1999" NAME="Lindstrom 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindstrom T, Nystrom FH, Olsson AG, Ottosson AM, Arnqvist HJ</AU>
<TI>The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with Type 2 diabetes mellitus</TI>
<SO>Diabetic Medicine</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>10</NO>
<PG>820-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lins-1988" NAME="Lins 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lins PE, Lundblad S, Persson-Trotzig E, Adamson U</AU>
<TI>Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1988</YR>
<VL>223</VL>
<NO>2</NO>
<PG>171-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Longnecker-1986" NAME="Longnecker 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Longnecker MP, Elsenhans VD, Leiman SM, Owen OE, Boden G</AU>
<TI>Insulin and a sulfonylurea agent in non-insulin-dependent diabetes mellitus</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1986</YR>
<VL>146</VL>
<NO>4</NO>
<PG>673-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez-1999" NAME="Lopez 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez-Alvarenga JC, Aguilar-Salinas CA, Velasco-Perez ML, Arita-Melzer O, Guillen LE, Wong B, et al</AU>
<TI>Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus</TI>
<SO>Diabetes Obesity &amp; Metabolism</SO>
<YR>1999</YR>
<VL>1</VL>
<NO>1</NO>
<PG>29-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1986" NAME="Martin 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin DB</AU>
<TI>Type II diabetes: insulin versus oral agents</TI>
<SO>New England Journal of Medicine</SO>
<YR>1986</YR>
<VL>314</VL>
<NO>20</NO>
<PG>1314-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mauerhoff-1986" NAME="Mauerhoff 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mauerhoff T, Ketelslegers JM, Lambert AE</AU>
<TI>Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion</TI>
<SO>Diabete et Metabolisme</SO>
<YR>1986</YR>
<VL>12</VL>
<NO>1</NO>
<PG>34-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mezitis-1992" NAME="Mezitis 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mezitis NH, Heshka S, Saitas V, Bailey TS, Costa R, Pi-Sunyer FX</AU>
<TI>Combination therapy for NIDDM with biosynthetic human insulin and glyburide</TI>
<SO>Diabetes Care</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>2</NO>
<PG>265-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohan-1990" NAME="Mohan 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohan V, Snehalatha C, Ramachandran A, Viswanathan M</AU>
<TI>Combination therapy of glibenclamide and insulin in NIDDM patients with secondary failure to oral drugs. [see comments]</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>1990</YR>
<VL>38</VL>
<NO>8</NO>
<PG>537-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nathan-1988" NAME="Nathan 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nathan DM, Roussell A, Godine JE</AU>
<TI>Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1988</YR>
<VL>108</VL>
<NO>3</NO>
<PG>334-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niazi-1998" NAME="Niazi 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niazi R, Muzaffar Z</AU>
<TI>Comparison of bedtime NPH insulin or metformin combined with glibenclamide in secondary sulphonylurea failure in obese type II (NIDDM) patients</TI>
<SO>JPMA - Journal of the Pakistan Medical Association</SO>
<YR>1998</YR>
<VL>48</VL>
<NO>11</NO>
<PG>336-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niskanen-1992" NAME="Niskanen 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niskanen L, Lahti J, Uusitupa M</AU>
<TI>Morning or bed-time insulin with or without glibenclamide in elderly type 2 diabetic patients unresponsive to oral antidiabetic agents</TI>
<SO>Diabetes Res Clin Pract</SO>
<YR>1992</YR>
<VL>18</VL>
<PG>185-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okada-1996" NAME="Okada 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okada S</AU>
<TI>The effect of an alpha-glucosidase inhibitor and insulin on glucose metabolism and lipid profiles in non-insulin-dependent diabetes mellitus</TI>
<SO>Journal of International Medical Research</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>5</NO>
<PG>438-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Osei-1984" NAME="Osei 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Osei K, O'Dorisio TM, Falko JM</AU>
<TI>Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism</TI>
<SO>American Journal of Medicine</SO>
<YR>1984</YR>
<VL>77</VL>
<NO>6</NO>
<PG>1002-09</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panahloo-1998" NAME="Panahloo 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panahloo A, Mohamed Ali V, Andres C, Denver AE, Yudkin JS</AU>
<TI>Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes</TI>
<SO>Metabolism: Clinical &amp; Experimental</SO>
<YR>1998</YR>
<VL>47</VL>
<NO>6</NO>
<PG>637-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pasmantier-1990" NAME="Pasmantier 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pasmantier R, Chaiken RL, Hirsch SR, Lebovitz HE</AU>
<TI>Metabolic effects of combination glipizide and human proinsulin treatment in NIDDM</TI>
<SO>Diabetes Care</SO>
<YR>1990</YR>
<VL>13 Suppl 3</VL>
<PG>42-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peacock-1984" NAME="Peacock 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peacock I, Tattersall RB</AU>
<TI>The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin?</TI>
<SO>British Medical Journal Clinical Research Ed</SO>
<YR>1984</YR>
<VL>288</VL>
<NO>6435</NO>
<PG>1956-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polo-1998" NAME="Polo 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;0940-5429&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polo V, Saibene A, Pontiroli AE</AU>
<TI>Nicotinamide improves insulin secretin and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas</TI>
<SO>Acta Diabetologica</SO>
<YR>1998</YR>
<VL>35</VL>
<NO>1</NO>
<PG>61-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3679"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ponssen-2000" NAME="Ponssen 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponssen HH, Elte JW, Lehert P, Schouten JP, Bets D</AU>
<TI>Combined metformin and insulin therapy for patients with type 2 diabetes mellitus</TI>
<SO>Clinical Therapeutics</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>6</NO>
<PG>709-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quatraro-1986" NAME="Quatraro 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quatraro A, Consoli G, Ceriello A, Giugliano D</AU>
<TI>Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up</TI>
<SO>Diabete et Metabolisme</SO>
<YR>1986</YR>
<VL>12</VL>
<NO>6</NO>
<PG>315-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raskin-2001" NAME="Raskin 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J</AU>
<TI>A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>7</NO>
<PG>1226-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reich-1987" NAME="Reich 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reich A, Abraira C, Lawrence AM</AU>
<TI>Combined glyburide and insulin therapy in type II diabetes</TI>
<SO>Diabetes Research</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>2</NO>
<PG>99-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Relimpio-1998" NAME="Relimpio 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Relimpio F, Pumar A, Losada F, Mangas MA, Acosta D, Astorga R</AU>
<TI>Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial</TI>
<SO>Diabetic Medicine</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>12</NO>
<PG>997-1002</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rivellese-2000" NAME="Rivellese 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rivellese AA, Patti L, Romano G, Innelli F, Di Marino L, Annuzzi G, et al</AU>
<TI>Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>11</NO>
<PG>4188-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-1998" NAME="Robinson 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;0149-5992&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS</AU>
<TI>The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>5</NO>
<PG>701-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3683"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodier-1995" NAME="Rodier 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodier M</AU>
<TI>Effects of insulin therapy upon plasma lipid fatty acids and platelet aggregation in NIDDM with secondary failure to oral antidiabetic agents</TI>
<SO>Diabetes Research and Clinical Practice</SO>
<YR>1995</YR>
<VL>28</VL>
<NO>1</NO>
<PG>19-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romano-1997" NAME="Romano 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romano G, Patti L, Innelli F, Di Marino L, Annuzzi G, Iavicoli M, et al</AU>
<TI>Insulin and sulfonylurea therapy in NIDDM patients. Are the effects on lipoprotein metabolism different even with similar blood glucose control?</TI>
<SO>Diabetes</SO>
<YR>1997</YR>
<VL>46</VL>
<PG>1601-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosak-1985" NAME="Rosak 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosak C, Schwarz O, Althoff PH, Schoffling K, Schmidt FH</AU>
<TI>[Combined treatment of type-2 diabetics with insulin and glibenclamide after secondary drug failure. Double-blind, insulin-placebo-controlled crossover study]. [German]</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1985</YR>
<VL>110</VL>
<NO>51-52</NO>
<PG>1975-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samanta-1987" NAME="Samanta 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samanta A, Burden AC, Kinghorn HA</AU>
<TI>A comparative study of sulphonylurea and insulin therapy in non insulin dependent diabetics who had failed on diet therapy alone</TI>
<SO>Diabetes Research</SO>
<YR>1987</YR>
<VL>4</VL>
<PG>183-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez-1999" NAME="Sanchez 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez-Barba Izquierdo MI, Ibarra Rueda JM, Ruiz de Adana PR</AU>
<TI>[The combination of insulin and metformin in obese patients with type-2 diabetes mellitus]. [Spanish]</TI>
<SO>Atencion Primaria</SO>
<YR>1999</YR>
<VL>24</VL>
<NO>8</NO>
<PG>462-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sane-1992" NAME="Sane 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Cn-00043151 - cctr RCT Medline 92211283&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sane T, Helve E, Yki-Järvinen H, Taskinen MR</AU>
<TI>One-year response to evening insulin therapy in non-insulin- dependent diabetes</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1992</YR>
<VL>231</VL>
<PG>253-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4839"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sangiorgio-1996" NAME="Sangiorgio 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;UI - 97122686&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sangiorgio L, Rabuazzo MA, Cordaro G, Grasso G, Condorelli L, Lunetta M</AU>
<TI>[Comparative study of the efficiency of ultralente insulin and NPH insulin combined with sulfonylurea in type 2 diabetes patients with secondary tolerance to sulfonylurea. Possible selection criteria]</TI>
<SO>Minerva Endocrinol</SO>
<YR>1996</YR>
<VL>21</VL>
<NO>2</NO>
<PG>47-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3681"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schade-1987" NAME="Schade 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schade DS, Mitchell WJ, Griego G</AU>
<TI>Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial</TI>
<SO>JAMA</SO>
<YR>1987</YR>
<VL>257</VL>
<NO>18</NO>
<PG>2441-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-1997" NAME="Schwartz 1997" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz SL, Fischer JS, Kipnes MS, Boyle M</AU>
<TI>Effects of short-term insulin therapy upon therapeutic response to glipizide</TI>
<SO>American Journal of Medicine</SO>
<YR>1987</YR>
<VL>83</VL>
<NO>3A</NO>
<PG>22-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-1998" NAME="Schwartz 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz S, Raskin P, Fonseca V, Graveline JF</AU>
<TI>Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. [see comments]</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<NO>13</NO>
<PG>861-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simonson-1987" NAME="Simonson 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simonson DC, Delprato S, Castellino P, Groop L, DeFronzo RA</AU>
<TI>Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients</TI>
<SO>Diabetes</SO>
<YR>1987</YR>
<VL>36</VL>
<NO>2</NO>
<PG>136-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1990" NAME="Simpson 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson HC, Sturley R, Stirling CA, Reckless JP</AU>
<TI>Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients</TI>
<SO>Diabetic Medicine</SO>
<YR>1990</YR>
<VL>7</VL>
<NO>2</NO>
<PG>143-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sinagra-1998" NAME="Sinagra 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sinagra D, Scarpitta AM, Amato M</AU>
<TI>Effects of insulin-oral hypoglycemic agents combined therapy in outpatients with type 2 diabetes</TI>
<SO>European Review for Medical &amp; Pharmacological Sciences</SO>
<YR>1998</YR>
<VL>2</VL>
<NO>5-6</NO>
<PG>175-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soneru-1993" NAME="Soneru 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soneru IL, Agrawal L, Murphy JC, Lawrence AM, Abraira C</AU>
<TI>Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure</TI>
<SO>Diabetes Care</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>6</NO>
<PG>896-901</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sotaniemi-1990" NAME="Sotaniemi 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sotaniemi EA, Vierimaa E, Huupponen R, Karvonen I, Vuoti MJ, Rytomaa K</AU>
<TI>Insulin and sulphonylurea in the therapy of type 2 diabetes</TI>
<SO>Diabetes Research and Clinical practice</SO>
<YR>1990</YR>
<VL>8</VL>
<PG>243-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Standl-1999" NAME="Standl 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Standl E, Baumgartl HJ, Fuchtenbusch M, Stemplinger J</AU>
<TI>Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy</TI>
<SO>Diabetes Obesity &amp; Metabolism</SO>
<YR>1999</YR>
<VL>1</VL>
<NO>4</NO>
<PG>215-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stenman-1988" NAME="Stenman 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stenman S, Groop PH, Saloranta C, Totterman KJ, Fyhrqvist F, Groop L</AU>
<TI>Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents</TI>
<SO>Diabetologia</SO>
<YR>1988</YR>
<VL>31</VL>
<NO>4</NO>
<PG>206-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stocks-1988" NAME="Stocks 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stocks AE MAH</AU>
<TI>Lack of effect of glibenclamide on insulin requirements and diabetic control in persons with insulin-dependent diabetes</TI>
<SO>Medical Journal of Australia</SO>
<YR>1988</YR>
<VL>149</VL>
<NO>9</NO>
<PG>472-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stradner-1990" NAME="Stradner 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;UI - 90327014&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stradner F, Pieber T, Toplak H, Schreiber U, Pfeiffer KP</AU>
<TI>[Insulin-sulfonylurea combination therapy in secondary therapy failure with sulfonylurea compounds. Randomized study between evening and morning intermediary insulin administration using the Novo Pen semi- automatic insulin injector]</TI>
<SO>Schweizerische medizinische Wochenschrift</SO>
<YR>1990</YR>
<VL>120</VL>
<NO>27-28</NO>
<PG>989-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4250"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1998" NAME="Thompson 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG</AU>
<TI>Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>6</NO>
<PG>987-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tovi-1998" NAME="Tovi 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tovi J, Ingemansson SO, Engfeldt P</AU>
<TI>Insulin treatment of elderly type 2 diabetic patients: effects on retinopathy</TI>
<SO>Diabetes &amp; Metabolism</SO>
<YR>1998</YR>
<VL>24</VL>
<NO>5</NO>
<PG>442-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trischitta-1992" NAME="Trischitta 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trischitta V, Italia S, Mazzarino S, Buscema M, Rabuazzo AM, Sangiorgio, L, et al</AU>
<TI>Comparison of combined therapies in treatment of secondary failure to glyburide</TI>
<SO>Diabetes Care</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>4</NO>
<PG>539-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trischitta-1998" NAME="Trischitta 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trischitta V, Italia S, Raimondo M, Guardabasso V, Licciardello C, Runello F, et al</AU>
<TI>Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?</TI>
<SO>Journal of Endocrinological Investigation</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>11</NO>
<PG>744-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trznadel-1997" NAME="Trznadel 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;UI - 97451845&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trznadel-Morawska I, Malecki M, Sieradzki J</AU>
<TI>[Estimation of different models of insulin therapy in noninsulin-dependent diabetes mellitus]</TI>
<SO>Przeglad lekarski</SO>
<YR>1997</YR>
<VL>54</VL>
<NO>5</NO>
<PG>308-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3680"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turner-1999-_x0028_2_x0029_" NAME="Turner 1999 (2)" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turner RC, Cull CA, Frighi V, Holman RR</AU>
<TI>Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>281</VL>
<NO>21</NO>
<PG>2005-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UKPDS-13-1995" NAME="UKPDS 13 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. [see comments]</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>310</VL>
<NO>6972</NO>
<PG>83-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UKPDS-24-1998" NAME="UKPDS 24 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. [see comments]</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1998</YR>
<VL>128</VL>
<NO>3</NO>
<PG>165-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UKPDS-33-1998" NAME="UKPDS 33 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. [see comments]. [erratum appears in Lancet 1999 Aug 14;354(9178):602]</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9131</NO>
<PG>837-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vigneri-1991" NAME="Vigneri 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vigneri R, Trischitta V, Italia S, Mazzarino S, Rabuazzo MA, Squatrito, S.</AU>
<TI>Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed-time NPH insulin to glyburide</TI>
<SO>Diabete et Metabolisme</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>1 Pt 2</NO>
<PG>232-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolffenbuttel-1989" NAME="Wolffenbuttel 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolffenbuttel BH, Weber RF, van Koetsveld PM, Weeks L, Verschoor L</AU>
<TI>A randomized crossover study of sulphonylurea and insulin treatment in patients with type 2 diabetes poorly controlled on dietary therapy</TI>
<SO>Diabetic Medicine</SO>
<YR>1989</YR>
<VL>6</VL>
<PG>520-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yki_x002d_Jarvinen-2000" NAME="Yki-Jarvinen 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yki-Jarvinen H, Dressler A, Ziemen M, HOE 901/300s Study, Group.</AU>
<TI>Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group</TI>
<SO>Diabetes Care</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>8</NO>
<PG>1130-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-1999" NAME="Yu 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu JG, Kruszynska YT, Mulford MI, Olefsky JM</AU>
<TI>A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients</TI>
<SO>Diabetes</SO>
<YR>1999</YR>
<VL>48</VL>
<NO>12</NO>
<PG>2414-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yudkin-2000" NAME="Yudkin 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yudkin JS, Panahloo A, Stehouwer C, Emeis JJ, Bulmer K, Mohamed-Ali V, Denver AE</AU>
<TI>The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects</TI>
<SO>Diabetologia</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>9</NO>
<PG>1099-1106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Goudswaard-2004" NAME="Goudswaard 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goudswaard AN, Stolk RP, Zuithoff P, de Valk HW, Rutten GE</AU>
<TI>Starting insulin in type 2 diabetes: Continue oral hypoglycemic agents? A randomized trial in primary care</TI>
<SO>Journal of Family Practice</SO>
<YR>2004</YR>
<VL>53</VL>
<NO>5</NO>
<PG>393-399</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olsson-2002" NAME="Olsson 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olsson PO, Lindstrom T</AU>
<TI>Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes</TI>
<SO>Diabetes Metab</SO>
<YR>2002</YR>
<VL>28</VL>
<NO>4 Pt 1</NO>
<PG>272-277</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stehouwer-2003" NAME="Stehouwer 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stehouwer MH, DeVries JH, Lumeij JA, Ader HJ, Engbers AM, Iperen AA, Snoek FJ, Heine RJ</AU>
<TI>Combined bedtime insulin-daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate-a randomised trial</TI>
<SO>Diabetes Metab Res Rev</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>2</NO>
<PG>148-152</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-03 17:21:45 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-03 17:21:45 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ADA-1997" NAME="ADA 1997" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetic Association</AU>
<TI>Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</TI>
<SO>Diabetes Care</SO>
<YR>1997</YR>
<VL>20</VL>
<PG>1183-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-1999" NAME="ADA 1999" TYPE="JOURNAL_ARTICLE">
<AU>The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</AU>
<TI>Report of The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</TI>
<SO>Diabetes Care</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>Suppl 1</NO>
<PG>S5-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Agurs-1997" NAME="Agurs 1997" TYPE="JOURNAL_ARTICLE">
<AU>Agurs Collins TD, Kumanyika SK, Ten Have TR, Adams Campbell LL.</AU>
<TI>A randomized controlled tria of weight reduction and exercise for diabetes management in older African-American subjects</TI>
<SO>Diabetes Care</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>10</NO>
<PG>1503-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Armitage-2002" NAME="Armitage 2002" TYPE="BOOK">
<AU>Armitage P, Berry G, Matthews JNS</AU>
<SO>Statistical methods in medical research, par. 5.3</SO>
<YR>2002</YR>
<PG>paragraph 5.3</PG>
<EN>4th edition</EN>
<PB>Blackwell Science</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bosello-1997" NAME="Bosello 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bosello O, Armellini F, Zamboni M, Fitchet M</AU>
<TI>The benefits of modest weight loss in type II diabetes</TI>
<SO>International Journal of Obesity and related Metabolic disorders</SO>
<YR>1997</YR>
<VL>21 Suppl 1</VL>
<PG>S10-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burgers-2002" NAME="Burgers 2002" TYPE="JOURNAL_ARTICLE">
<AU>Burgers JS, Bailey JV, Klazinga NS, van der Bij AK, Grol R, Feder G</AU>
<TI>Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>11</NO>
<PG>1933-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1960" MODIFIED="2008-10-03 17:15:53 +0200" MODIFIED_BY="[Empty name]" NAME="Cohen 1960" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J</AU>
<TI>A coefficient of agreement for nominal scales</TI>
<SO>Educational and psychological measurement</SO>
<YR>1960</YR>
<VL>20</VL>
<PG>37-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DCCT-1993" NAME="DCCT 1993" TYPE="JOURNAL_ARTICLE">
<TI>The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group</TI>
<SO>The New England journal of medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<PG>977-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Sonnaville-1998" NAME="de Sonnaville 1998" TYPE="JOURNAL_ARTICLE">
<AU>Sonnaville de JJ, Snoek FJ, Colly LP, Deville W, Wijkel D, Heine RJ</AU>
<TI>Well-being and symptoms in relation to insulin therapy in type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>6</NO>
<PG>919-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2008-10-03 17:15:58 +0200" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled clinical trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="28"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey SG, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garber-2003" NAME="Garber 2003" TYPE="JOURNAL_ARTICLE">
<AU>Garber AJ</AU>
<TI>Benefits of combination therapy of insulin and oral hypoglycemic agents</TI>
<SO>Archives of internal medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<NO>15</NO>
<PG>1781-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goddijn-1999" NAME="Goddijn 1999" TYPE="JOURNAL_ARTICLE">
<AU>Goddijn PP, Bilo HJ, Feskens EJ, Groenier KH, van der Zee KI, Meyboom-de Jong B</AU>
<TI>Longitudinal study on glycaemic control and quality of life in patients with Type 2 diabetes mellitus referred for intensified control</TI>
<SO>Diabetic Medicine</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>1</NO>
<PG>23-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: Is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-1996" NAME="Johnson 1996" TYPE="JOURNAL_ARTICLE">
<AU>Johnson JL, Wolf SL, Kabadi UM</AU>
<TI>Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials</TI>
<SO>Archives of internal medicine</SO>
<YR>1996</YR>
<VL>156</VL>
<NO>3</NO>
<PG>259-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lau-1997" MODIFIED="2008-10-03 17:16:04 +0200" MODIFIED_BY="[Empty name]" NAME="Lau 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lau J, Loannidis JPA, Schmid CH</AU>
<TI>Quantitative synthesis in systematic reviews</TI>
<SO>Annals of internal medicine</SO>
<YR>1997</YR>
<VL>127</VL>
<PG>820-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Little-1986" NAME="Little 1986" TYPE="JOURNAL_ARTICLE">
<AU>Little RR, England JD, Wiedmeyer HM, McKenzie EM, Mitra R, Erhart PM, Durham JB, Goldstein DE</AU>
<TI>Interlaboratory standardization of glycated hemoglobin determinations</TI>
<SO>Clinical chemistry</SO>
<YR>1986</YR>
<VL>32</VL>
<NO>2</NO>
<PG>358-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1997" MODIFIED="2008-10-03 17:16:09 +0200" MODIFIED_BY="[Empty name]" NAME="Mulrow 1997" TYPE="BOOK">
<AU>Mulrow CD, Oxman AD</AU>
<SO>Cochrane Collaboration Handbook</SO>
<YR>1997</YR>
<VL>4</VL>
<EN>updated September 1997</EN>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NDDG-1979" NAME="NDDG 1979" TYPE="JOURNAL_ARTICLE">
<AU>National Diabetes Data Group</AU>
<TI>Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance</TI>
<SO>Diabetes</SO>
<YR>1979</YR>
<VL>28</VL>
<PG>1039-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peters-1991" NAME="Peters 1991" TYPE="JOURNAL_ARTICLE">
<AU>Peters AL, Davidson MB</AU>
<TI>Insulin plus a sulfonylurea agent for treating type 2 diabetes</TI>
<SO>Annals of internal medicine</SO>
<YR>1991</YR>
<VL>115</VL>
<NO>1</NO>
<PG>45-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pugh-1992" NAME="Pugh 1992" TYPE="JOURNAL_ARTICLE">
<AU>Pugh-JA, Wagner-ML, Sawyer-J, Ramirez-G, Tuley-M, Friedberg-SJ</AU>
<TI>Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis [see comments]</TI>
<SO>Diabetes Care</SO>
<YR>1992</YR>
<VL>15</VL>
<PG>953-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riddle-2002" NAME="Riddle 2002" TYPE="JOURNAL_ARTICLE">
<AU>Riddle MC</AU>
<TI>Timely addition of insulin to oral therapy for type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>2</NO>
<PG>395-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riddle-2003" NAME="Riddle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Riddle MC, Rosenstock J, Gerich J</AU>
<TI>The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients</TI>
<SO>Diabetes Care</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>11</NO>
<PG>3080-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenthal-1994" MODIFIED="2008-10-03 17:16:14 +0200" MODIFIED_BY="[Empty name]" NAME="Rosenthal 1994" TYPE="BOOK_SECTION">
<AU>Rosenthal R</AU>
<TI>Parametric measures of effect size</TI>
<SO>The handbook of research synthesis</SO>
<YR>1994</YR>
<PG>231-44</PG>
<ED>Cooper H, Hedges HV</ED>
<PB>Sage Foundation</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ruige-1998" NAME="Ruige 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM</AU>
<TI>Insulin and risk of cardiovascular disease: a meta-analysis</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>97</VL>
<NO>10</NO>
<PG>996-1001</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stout-1990" NAME="Stout 1990" TYPE="JOURNAL_ARTICLE">
<AU>Stout RW</AU>
<TI>Insulin and atheroma. 20-yr perspective</TI>
<SO>Diabetes Care</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>6</NO>
<PG>631-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turner-1999" NAME="Turner 1999" TYPE="JOURNAL_ARTICLE">
<AU>Turner RC, Cull CA, Frighi V, Holman RR</AU>
<TI>Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>281</VL>
<NO>21</NO>
<PG>2005-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UKPDS-33" NAME="UKPDS 33" TYPE="JOURNAL_ARTICLE">
<TI>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>837-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Does-1996" NAME="van der Does 1996" TYPE="JOURNAL_ARTICLE">
<AU>Does van der FE, De Neeling JN, Snoek FJ, Kostense PJ, Grootenhuis PA, Bouter LM, Heine RJ</AU>
<TI>Symptoms and well-being in relation to glycemic control in type II diabetes</TI>
<SO>Diabetes Care</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>3</NO>
<PG>204-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Tulder-1997" MODIFIED="2008-10-03 17:16:21 +0200" MODIFIED_BY="[Empty name]" NAME="Van Tulder 1997" TYPE="JOURNAL_ARTICLE">
<AU>Van Tulder MW, Assendelft WJJ, Koes BW, Bouter LM</AU>
<TI>Method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group for Spinal Disorders</TI>
<SO>Spine</SO>
<YR>1997</YR>
<VL>22</VL>
<PG>2323-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Westphal-2003" NAME="Westphal 2003" TYPE="JOURNAL_ARTICLE">
<AU>Westphal SA, Palumbo PJ</AU>
<TI>Insulin and oral hypoglycemic agents should not be used in combination in the treatment of type 2 diabetes</TI>
<SO>Archives of internal medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<NO>15</NO>
<PG>1783-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1980" MODIFIED="2008-10-03 17:21:45 +0200" MODIFIED_BY="[Empty name]" NAME="WHO 1980" TYPE="OTHER">
<AU>WHO Expert Committee on Diabetes Mellitus</AU>
<TI>Second report. Technical Report Series 646</TI>
<SO>Geneva. WHO, 1980</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1985" MODIFIED="2008-10-03 17:20:04 +0200" MODIFIED_BY="[Empty name]" NAME="WHO 1985" TYPE="OTHER">
<TI>WHO Expert Committee on Diabetes Mellitus</TI>
<SO>World Health Organization, 1985. Technical Report Series 727</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1999" NAME="WHO 1999" TYPE="BOOK_SECTION">
<AU>World Health Organization</AU>
<TI>Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus</TI>
<YR>1999</YR>
<PG>1-59</PG>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="179"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yki_x002d_J_x00e4_rvinen-2000" NAME="Yki-Järvinen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Yki-Järvinen H, Dressler A, Ziemen M</AU>
<TI>Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group</TI>
<SO>Diabetes Care</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>8</NO>
<PG>1130-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yki_x002d_J_x00e4_rvinen-2001" NAME="Yki-Järvinen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Yki-Järvinen H</AU>
<TI>Combination therapies with insulin in type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>4</NO>
<PG>758-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zavaroni-1989" NAME="Zavaroni 1989" TYPE="JOURNAL_ARTICLE">
<AU>Zavaroni I, Bonora E, Pagliara M, Dall'Aglio E, Luchetti L, Buonanno G, et al.</AU>
<TI>Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1989</YR>
<VL>320</VL>
<NO>11</NO>
<PG>702-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-10-28 13:37:31 +0100" MODIFIED_BY="Gudrun Paletta">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-10-28 13:37:31 +0100" MODIFIED_BY="Gudrun Paletta" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bachmann-1988">
<CHAR_METHODS>
<P>Design: randomised placebo controlled trial<BR/>Duration: 6 months<BR/>Randomisation procedure: unclear<BR/>Blinding: patients yes; care provider yes; outcome assessor unclear<BR/>Intention to treat: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Setting: secondary care outpatient<BR/>Inclusion criteria: &gt; 40 years; &gt; 3 year SU therapy; &gt; 3 months max. SU therapy; FBG &gt; 12.2 mmol/l or post-prandial BG &gt; 15.5 mmol/l; bodyweight &lt; 150% of &#8217;ideal bodyweight&#8217; <BR/>Exclusion criteria: unclear<BR/>Patients randomised: 140 <BR/>Nr of patients/group: unclear <BR/>Drop-outs / loss to follow-up: 72<BR/>Nr of patients/group analysed: 37 / 31<BR/>Age (years, median): 66 / 69<BR/>Sex (% male): 38 / 19<BR/>Diabetes duration (years, median): 10 / 12<BR/>Diabetes therapy: glibenclamide 15 mg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: mixed insulin (25% regular / 75% protamine insulin) + glibenclamide 15 mg<BR/>Group 2: mixed insulin (25% regular / 75% protamine insulin) + placebo<BR/>Glucose targets to which insulin doses were titrated: FBG &lt;= 10 mmol/l and post-prandial BG £ 12.2 mmol/l<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: FBG, post-prandial BG, HbA1<BR/>Weight: Weight<BR/>Insulin amount (E): mean daily insulin dose at final visit<BR/>Hypoglycaemia: hypoglycaemic episodes<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: not reported <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 2<BR/>Characteristics only available for analysed patients; presented as median values<BR/>Sponsoring: not specified<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bastyr-1999">
<CHAR_METHODS>
<P>Design: randomised controlled trial<BR/>Duration: 2 months<BR/>Randomisation procedure: computer generated<BR/>Blinding: patients no; care provider no; outcome assessor no<BR/>Intention to treat: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA, Europe<BR/>Setting: secondary care outpatient, 58 centers, 11 countries<BR/>Inclusion criteria: 40-85 year; type 2 diabetes according to WHO; secondary failure on SU; FBG &gt; 7.8 mmol/l or AMBG &gt; 10.0 mmol/l or HbA1c &gt; 150% of the upper limit of the non-diabetic range at the local laboratory<BR/>Exclusion criteria: unclear<BR/>Patients randomised: 423 Nr of patients/group: 139 / 149 / 135 <BR/>Drop-outs / loss to follow-up: 27<BR/>Nr of patients/group analysed: 139 / 149 / 135<BR/>Age (years, median): 60.1 / 59.6 / 60.7 <BR/>Sex (% male): 44 / 58 / 54 <BR/>Diabetes duration (years): 10 / 9 / 9<BR/>Diabetes therapy: unclear<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: pre-prandial insulin Lispro + glibenclamide 15 mg (Europe) or glyburide 20 mg (USA)<BR/>Group 2: pre-prandial insulin Lispro + bedtime NPH insuline<BR/>Group 3: bedtime NPH insulin + glibenclamide 15 mg (Europe) or 20 mg (USA)<BR/>Glucose targets to which insulin doses were titrated: not available<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: FBG, post-prandial BG, HbA1c <BR/>Weight: body weight, BMI<BR/>Insulin amount (E): mean daily insulin dose at final visit<BR/>Hypoglycaemia: hypoglycaemic episodes,<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: reported <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 3<BR/>Sponsoring: pharmaceutical<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chow-1995">
<CHAR_METHODS>
<P>Design: randomised controlled trial<BR/>Duration: 8 months<BR/>Randomisation procedure: &#8220;consecutively and alternately&#8221; <BR/>Blinding: patients no ; care provider no ; outcome assessor no<BR/>Intention to treat: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Hong Kong<BR/>Setting: secondary care outpatients<BR/>Inclusion criteria: age &gt; 20 year and maximum dose of SU and/or metformin and FPG &gt; 7.8 mmol/l<BR/>Exclusion criteria: MI, CCF, PVD, renal failure, hepatic disease, proliferative retinopathy, severe maculopathy, insulin-dependent diabetes, previous treatment with insulin, excessive alcohol consumption, night-shift work.<BR/>Patients randomised: 55<BR/>Nr of patients/group: 28 / 27<BR/>Drop-outs / loss to follow-up: 1 / 1<BR/>Nr of patients/group analysed: 27 / 26 <BR/>Age (years): 57 / 51<BR/>Sex (% male): 33 / 35<BR/>Diabetes duration (years): 9.9 / 8.0 <BR/>Diabetes therapy: SU (10), SU+metformin (17) / SU (9), SU+metformin (17)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: OHA continued + intermediate-acting insulin (NPH) before bedtime <BR/>Group 2: intermediate-acting insulin (NPH) before breakfast (a dinner injection was added when &gt; 24 U were needed) (1 patient received NPH/regular insulin 70/30)<BR/>Glucose targets to which insulin doses were titrated: FPG &lt; 7.8 mmol/l (both groups) and post-prandial PG &lt; 11.1 mmol/l (group 2)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: FPG, HbA1c<BR/>Weight: body weight, BMI<BR/>Insulin amount (E): insulin doses at 6 months<BR/>Hypoglycaemia: hypoglycaemia <BR/>Well-being: well-being questionnaire <BR/>Treatment Satisfaction: injection pain and problems questionnaire <BR/>Adverse events: not reported <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 1<BR/>Sponsoring: pharmaceutical<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-F_x00f6_v_x00e9_nyi-1997">
<CHAR_METHODS>
<P>Design: Randomised controlled trial<BR/>Duration: 3 years<BR/>Randomisation procedure: unclear <BR/>Blinding: patients no; care provider no; outcome assessor no <BR/>Intention to treat: no<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Hungary<BR/>Setting: Secondary care outpatient, single centre<BR/>Inclusion criteria: HbA1c &gt; 7.5% (normal range not given, HPLC assay) despite max. Sulphonylurea therapy (± acarbose, ±biguanide)<BR/>Exclusion criteria: unclear <BR/>Patients randomised: 286<BR/>Nr of patients/group: 141 / 145<BR/>Drop-outs / loss to follow-up: 82 (58.2%) subjects from group 1 switched to twice daily conventional insulin treatment because of insufficient glycaemic control<BR/>Nr of patients/group analysed: 141 / 145<BR/>Age (years, mean): 59.8 yrs / 60.5 yrs <BR/>Sex (% male): 41.8% / 40.7%<BR/>Diabetes duration (years): 10.2 / 10.5<BR/>Diabetes therapy: Glibenclamide 96%, Gliclazide 4%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Sulphonylurea (dose unchanged) + bedtime NPH insulin (6-10 units initially)<BR/>Group 2: Twice daily conventional insulin (not specified)<BR/>Glucose targets to which insulin doses were titrated: Fasting blood glucose &lt; 7.0 mmol/l<BR/>Pre-prandial / bedtime &lt;10.0 mmol/l<BR/>Max dose of bedtime NPH allowed = 40 units, above this converted to twice daily insulin.<BR/>If FBG &lt;7.0 mmol/l, but daytime &gt;10.0 mmol/l, NPH changed to long-acting insulin (Humulin U or Ultratard).<BR/>Max dose of long acting insulin allowed = 28 units, above this converted to twice daily insulin.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: HbA1c (method and normal range not given) <BR/>Weight: Weight gain<BR/>Insulin amount (E): Mean daily insulin dose at final visit <BR/>Hypoglycaemia: not reported<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: not reported <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 1 (drop-outs described)<BR/>Sponsoring: not stated<BR/>No predetermined time for end-point analyses. Patients randomised to one or other treatment and analysed 3.5 years after recruitment commenced. Duration of follow-up therefore variable (expressed as mean ± SD).<BR/>Analysis not intention to treat. Large drop-out of subjects from combination therapy group. Subjects analysed as 3 separate groups. 1. SU/insulin. 2. Twice daily insulin. 3. Converted from SU/insulin to twice daily insulin.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gutniak-1987">
<CHAR_METHODS>
<P>Design: double-blind placebo controlled trial<BR/>Duration: 10½ months<BR/>Randomisation procedure: unclear <BR/>Blinding: patients yes; care provider yes; outcome assessor unclear <BR/>Intention to treat: unclear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Sweden<BR/>Setting: secondary care outpatient<BR/>Inclusion criteria: pre-prandial BG &gt; 11 mmol/l in 50% of the samples during 1 months unless diet, exercise, and 28 mg glyburide<BR/>Exclusion criteria: unclear<BR/>Patients randomised: 20<BR/>Nr of patients/group: 10 / 10<BR/>Drop-outs / loss to follow-up: 0 <BR/>Nr of patients/group analysed: 10 / 10 <BR/>Age (years): 57<BR/>Sex (% male): unclear <BR/>Diabetes duration (years): 14.1 <BR/>Diabetes therapy: glyburide 20 mg / day<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: mixed insulin (intermediate-acting (NPH) plus regular insulin) twice daily + glyburide 10,5 mg <BR/>Group 2: mixed insulin (intermediate-acting (NPH) plus regular insulin twice daily + placebo tablets<BR/>Glucose targets to which insulin doses were titrated: FBG &lt; 8 mmol/l and post-prandial BG &lt; 10 mmol/l<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glucose profile: FBG, HbA1c<BR/>Other: body weight, insulin amount <BR/>Adverse effects: hypoglycaemia<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 2<BR/>Sponsoring: pharmaceutical<BR/>SD calculated from SE; data in text don&#8217;t correspond with graphs<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Holman-1987">
<CHAR_METHODS>
<P>Design: cross-over study<BR/>Duration: 5 x 8 weeks<BR/>Randomisation procedure: unclear <BR/>Blinding: patients no; care provider no; outcome assessor no<BR/>Intention to treat: no<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United Kingdom<BR/>Setting: primary care<BR/>Inclusion criteria: maximal SU therapy, asymptomatic diabetes type 2<BR/>Exclusion criteria: retinopathy, cardiovascular disease <BR/>Patients randomised: 17<BR/>Drop-outs / loss to follow-up: 2 <BR/>Nr of patients analysed: 15<BR/>Age (years): 57<BR/>Sex (% male): 50<BR/>Diabetes duration (years): 8<BR/>Diabetes therapy: &#8216;maximal SU therapy&#8217;<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: maximal SU <BR/>Group 2: maximal SU + metformin<BR/>Group 3: maximal SU + long-acting insulin once daily<BR/>Group 4: long-acting insulin once daily<BR/>Group 5: long-acting insulin once daily + short-acting insulin twice daily<BR/>Glucose targets to which insulin doses were titrated: FPG &lt; 6 mmol/l<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: basal PG, HbA1<BR/>Weight: body weight<BR/>Insulin amount (E): insulin amount<BR/>Hypoglycaemia: hypoglycaemia reported<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 1<BR/>Sponsoring: unclear<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-03 17:22:37 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karlander-1991">
<CHAR_METHODS MODIFIED="2008-10-03 17:22:37 +0200" MODIFIED_BY="[Empty name]">
<P>see <LINK REF="STD-Gutniak-1987" TYPE="STUDY">Gutniak 1987</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lotz-1988">
<CHAR_METHODS>
<P>Design: randomised controlled trial<BR/>Duration: 2 year<BR/>Randomisation procedure: &#8216;randomised order&#8217; (=alternately?)<BR/>Blinding: patients no ; care provider no ; outcome assessor no<BR/>Intention to treat: yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Setting: secondary care outpatient<BR/>Inclusion criteria: age 45-80; maximal OHAs &gt; 2 year; FBG &gt; 11.1 mmol/l; post-prandial BG &gt; 13.9 mmol/l; HbA1 &gt; 11.0%; weight &lt; 130% BROCA (length (cm) &#8211; weight (kg))<BR/>Exclusion criteria: unclear<BR/>Patients randomised: 16<BR/>Nr of patients/group: 8 / 8<BR/>Drop-outs / loss to follow-up: 0 / 0 <BR/>Nr of patients/group analysed: 8 / 8<BR/>Age (years): 65 / 59<BR/>Sex (% male): unclear<BR/>Diabetes duration (years): 15 / 11 <BR/>Diabetes therapy: SU (not specified)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: insulin (not specified), twice daily<BR/>Group 2: intermediate-insulin once a day + glibenclamide 7 mg<BR/>Glucose targets to which insulin doses were titrated: unclear <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: FBG, HbA1 (Biorad) <BR/>Weight: weight (% BROCA)<BR/>Insulin amount (E): daily insulin dose at final visit <BR/>Hypoglycaemia: qualitatively reported<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: not reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 1<BR/>Sponsoring: not reported<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lundershausen-1987">
<CHAR_METHODS>
<P>Design: randomised controlled trial<BR/>Duration: 6 months<BR/>Randomisation procedure: not reported <BR/>Blinding: patients yes; care provider yes; outcome assessor unclear <BR/>Intention to treat: yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Setting: unclear<BR/>Inclusion criteria: maximal SU (glibenclamide 15 mg) and FBG &gt; 10 mmol/l, <BR/>Exclusion criteria: infections, kidney failure, liver disease, neoplasia, other metabolic disorders, co-medication interfering with glucose metabolism<BR/>Patients randomised: 79<BR/>Nr of patients/group: 39 / 40<BR/>Drop-outs / loss to follow-up: 0 / 0<BR/>Nr of patients/group analysed: 39 / 40<BR/>Age (years): 62 / 62<BR/>Sex (% male): 38 / 33 <BR/>Diabetes duration (years): 11 / 11 <BR/>Diabetes therapy: glibenclamide 15 mg<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: insulin + glibenclamide 10 mg<BR/>Group 2: insulin + placebo <BR/>Glucose targets to which insulin doses were titrated: mean glucose value 12 mmol/l <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: &#8220;glucose value according to Michaelis&#8221; (normal values good: &lt; 11 mmol/l; acceptable &gt;11 &lt; 16.5 mmol/l; poor &gt; 16.5 mmol/l)<BR/>Weight: weight change; BMI change (only reported for all patients)<BR/>Insulin amount: daily insulin dose <BR/>Hypoglycaemia: qualitatively reported<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 3<BR/>Sponsoring: not reported<BR/>Type of insulin not specified<BR/>One year follow-up study, however at six months 41 patients discontinued oral medication<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-28 13:37:31 +0100" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-M_x00e4_kimattila-1999">
<CHAR_METHODS MODIFIED="2008-10-28 13:37:31 +0100" MODIFIED_BY="Gudrun Paletta">
<P>see Yki-Järvinen 1999</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pontiroli-1990">
<CHAR_METHODS>
<P>Design: Randomised cross-over controlled trial<BR/>Duration: 2x 3 month treatment periods<BR/>Randomisation procedure: unclear<BR/>Blinding: patients no; care provider no; outcome assessor unclear<BR/>Intention to treat: no<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Italy<BR/>Setting: not stated<BR/>Inclusion criteria: &#8220;Poor metabolic control&#8221; despite glibenclamide 15 mg/day, normal bodyweight (IBW ±10%, Metropolitan Life Insurance tables)<BR/>Exclusion criteria: Ischaemic heart disease, congestive cardiac failure, &#8220;renal impairment&#8221;, &#8220;hepatic impairment&#8221;, &#8220;dyslipidaemia&#8221;<BR/>Patients randomised: 10<BR/>Nr of patients/group: 5 / 5<BR/>Drop-outs / loss to follow-up: 1 non-completer<BR/>Nr of patients/group analysed: 9 (total)<BR/>Age (years, mean): 61 yrs (all subjects)<BR/>Sex (% male): 60% male (all subjects)<BR/>Diabetes duration (years): 12.8 yrs (all subjects)<BR/>Diabetes therapy: Glibenclamide 15 mg/day (3-month run-in period)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Glibenclamide 5mg tds + am ultralente insulin<BR/>Group 2: am ultralente insulin alone<BR/>Cross-over after 3 months, no washout period, carry-over effect not described</P>
<P>Glucose targets to which insulin doses were titrated: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: HbA1c (HPLC method, normal range not given)<BR/>Weight: Weight gain (comment only, no data)<BR/>Hypoglycaemia: not reported<BR/>Insulin amount (E): Mean daily insulin dose at final visit<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse effects: not reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 1 (drop-outs (n=1) described)<BR/>Sponsoring: not stated<BR/>Outcome data extracted from figures.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ravnik_x002d_Oblak-1995">
<CHAR_METHODS>
<P>Design: Randomised crossover controlled trial<BR/>Duration: 2x 3 month treatment periods<BR/>Randomisation procedure: unclear<BR/>Blinding: patients no; care provider no; outcome assessor no.<BR/>Intention to treat: Yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Slovenia<BR/>Setting: Secondary care outpatient<BR/>Inclusion criteria: HbA1c &gt; 9.0% despite glibenclamide 10 mg bd, FBG &gt; 10 mmol/l (for 3 months), Age &gt;35 years, Diabetes duration &gt; 3 years, BMI &lt; 30 kg/m2, Fasting C-peptide &gt; 0.3 mmol/l<BR/>Exclusion criteria: Liver disease, renal disease, heart failure, myocardial infarction within 6 months, medication with potential to interact with oral hypoglycaemic agents or insulin. <BR/>Patients randomised: 27<BR/>Nr of patients/group: 14 / 13<BR/>Drop-outs / loss to follow-up: nil<BR/>Nr of patients/group analysed: 27 (total)<BR/>Age (years, median): 58 yrs (all subjects)<BR/>Sex (% male): 56% (all subjects)<BR/>Diabetes duration (years, median): 10.5 / 8<BR/>Diabetes therapy: glibenclamide 10 mg bd (no run-in period)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Glibenclamide 10 mg bd + insulin (combination of short and intermediate acting insulin ( Actrapid HM, Protophane HM (Novo Nordisk) once or twice daily)<BR/>Group 2: Insulin alone<BR/>Cross-over after 3 months, no wash-out period, carry-over effect not described.<BR/>Glucose targets to which insulin doses were titrated: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: HbA1c (normal range &lt;6.5%, HPLC assay)<BR/>Weight: BMI<BR/>Insulin amount (E): Median daily insulin dose at final visit<BR/>Hypoglycaemia: not reported<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: not reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 2 (no drop-outs, therefore also ITT analysis)<BR/>Sponsoring: not stated<BR/>Outcome data extracted from figures.<BR/>Data expressed as median values<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Riddle-1989">
<CHAR_METHODS>
<P>Design: Randomised crossover controlled trial<BR/>Duration: 2x 4 month treatment periods<BR/>Randomisation procedure: Performed centrally by drug manufacturer (sequentially numbered supplies of study drug matched to subjects place in sequence of enrolment). <BR/>Blinding: patients yes; care provider yes; outcome assessor yes.<BR/>Intention to treat: No<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Oregon, USA<BR/>Setting: Secondary care outpatient<BR/>Inclusion criteria: Age 40-75 yrs, diabetes (gradual) onset &gt; 35 yrs of age, diabetes duration &gt;1 but &lt;15 yrs, weight &lt; 160% ideal bodyweight (Metropolitan Life Insurance tables, 1983), sub-optimal glycaemic control on current therapy - fasting plasma glucose &gt;7.8 mmol/l.<BR/>Exclusion criteria: Major systemic illness other than diabetes, alcoholism, pancreatitis, pancreatic resection, use of corticosteroids, any disability likely to interfere with adherence to the trial protocol.<BR/>Patients randomised: 21<BR/>Nr of patients/group: 10 / 11 <BR/>Drop-outs / loss to follow-up: 0 / 1<BR/>Nr of patients/group analysed: 10/10<BR/>Age (years, mean): 61 yrs (all subjects) <BR/>Sex (% male): 40% male (all subjects)<BR/>Diabetes duration (years, mean): 6 years <BR/>Diabetes therapy: Glibenclamide 10 mg bd (2-8 week run-in period)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Glibenclamide 10 mg + evening porcine NPH (Insulatard, Novo Nordisk)<BR/>Group 2: Placebo + evening porcine NPH<BR/>Crossover after 4 months, no washout period, treatment effect described<BR/>Glucose targets to which insulin doses were titrated: Insulin increased at the physicians&#8217; discretion aiming for &#8220;excellent glycaemic control&#8221;.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: HbA1 (thiobarbituric acid method, normal range 5.3-8.9%), FPG<BR/>Weight: Weight gain<BR/>Insulin amount (E): Mean daily insulin dose at final visit<BR/>Hypoglycaemia: Mentioned in text, no data<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: Reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 6 (not ITT)<BR/>Sponsoring: Financial support from Upjohn and the American Diabetes Association Oregon Affiliate<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Riddle-1992">
<CHAR_METHODS>
<P>Design: Double-blind randomised placebo-controlled trial<BR/>Duration: 16 weeks<BR/>Randomisation procedure: Randomised at time of entry into the treatment protocol by assignment of a study number corresponding to a treatment code determined by the drug manufacturer.<BR/>Blinding: patients yes; care provider yes; outcome assessor yes.<BR/>Intention to treat: Yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Oregon, USA<BR/>Setting: Secondary care outpatient<BR/>Inclusion criteria: Diabetes of gradual onset &gt; 40 yrs of age, diabetes duration &gt;1 yr, fasting plasma glucose &gt;7.8 mmol/l despite glibenclamide 10 mg bd.<BR/>Exclusion criteria: Major systemic illness other than diabetes. Use of corticosteroids, oestrogen, thyroxine, Adrenergic blockers or diuretics within 1 month of study entry. Patients randomised: 21<BR/>Nr of patients/group: 11 / 10<BR/>Drop-outs / loss to follow-up: nil <BR/>Nr of patients/group analysed: 11/10<BR/>Age (years, mean): 55 / 52 yrs <BR/>Sex (% male): not stated<BR/>Diabetes duration (years): 6 / 4<BR/>Diabetes therapy: glibenclamide 10 mg bd (3-week run-in period)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Glibenclamide 10 mg pre-breakfast + suppertime Novolin 70:30 insulin (Novo Nordisk human 70% NPH, 30% soluble)<BR/>Group 2: Placebo + suppertime 70:30 insulin<BR/>Glucose targets to which insulin doses were titrated:<BR/>Subjects asked to measure capillary blood glucose (CPG) daily before breakfast and supper<BR/>Insulin starting dose + 30 units, increased weekly,<BR/>If mean CBG &gt; 10 mmol/l, insulin increased by 20 units<BR/>CBG 7.8-10, insulin increased by 15 units<BR/>CBG 6.7-7.8 mmol/l, insulin increased by 10 units<BR/>CBG 5.6- 6.7 mmol/l, insulin increased by 5 units<BR/>If recurrent hypoglycaemic symptoms, or repeated CBG &lt; 3.3 mmol/l, reduce by 5-10 units<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: HbA1 (thiobarbituric acid method, normal range 5.3-8.9%), FPG<BR/>Weight: Weight gain<BR/>Insulin amount (E): Mean daily insulin dose at final visit<BR/>Hypoglycaemia: Symptomatic hypoglycaemic episodes<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: not reported <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 7<BR/>Sponsoring: Support by a research grant from Hoechst-Roussel Pharmaceuticals</P>
<P>Structured insulin titration regimen<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Riddle-1998">
<CHAR_METHODS>
<P>Design: Double-blind randomised placebo-controlled trial<BR/>Duration: 24 weeks<BR/>Randomisation procedure: not stated<BR/>Blinding: patients yes; care provider yes; outcome assessor yes.<BR/>Intention to treat: Yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Oregon, USA<BR/>Setting: Secondary care outpatient <BR/>Inclusion criteria: Age 45-70 yrs, weight 130-170% IBW, FPG 10.0-16.7 mmol/l with glimepiride 8mg bd, adequate contraception<BR/>Exclusion criteria: Pregnancy, breast feeding, DM duration &gt; 15 yrs, history of ketoacidosis, autoimmune disease, any major systemic illness other than diabetes, allergy or intolerance to sulphonylureas, use of glucocorticoids, phenytoin, nicotinic acid, sympathomimetics, phenothiazines, isoniazid. Serum creatinine or serum alanine aminotransferase &gt;1.5 times upper limit of normal; fasting C-peptide &lt; 0.4 pmol/l. <BR/>Patients randomised: 145<BR/>Nr of patients/group: 72 / 73<BR/>Drop-outs / loss to follow-up: 2 / 11<BR/>Nr of patients/group analysed: 72 / 73<BR/>Age (years, mean): 58 / 58 yrs <BR/>Sex (% male): 63% / 55%<BR/>Diabetes duration (years): 7 / 7yrs<BR/>Diabetes therapy: Glimepiride 8 mg bd (8-week run-in period)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Glimepiride 8mg bd + suppertime 70:30 insulin (70%NPH / 30% regular human insulin)<BR/>Group 2: Placebo + suppertime 70:30 insulin<BR/>Glucose targets to which insulin doses were titrated: FBG 5.5-6.7 mmol/l <BR/>Subjects asked to measure capillary blood glucose (CPG) daily before breakfast and supper<BR/>Insulin starting dose = 10 units for 2 weeks, then Increased weekly<BR/>by 10 units until FBG &lt; 7.8 mmol/l for 2 consecutive days then,<BR/>by 5 units until FBG &lt; 6.7 mmol/l for 2 consecutive days then<BR/>Small reductions allowed if hypoglycaemic symptoms occurred<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: HbA1c (HPLC assay, normal range 4-6%), FPG<BR/>Weight: Weight gain<BR/>Insulin amount (E): Mean daily insulin dose at final visit<BR/>Hypoglycaemia: Symptomatic hypoglycaemic episodes<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: Reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 6 (randomisation method not stated)<BR/>Sponsoring: Support by a research grant from Hoechst Marion Roussel Pharmaceuticals<BR/>Structured insulin titration regimen<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shank-1995">
<CHAR_METHODS>
<P>Design: Double-blind randomised placebo-controlled trial<BR/>Duration: 6 months<BR/>Randomisation procedure: Randomisation code <BR/>Blinding: patients yes; care provider yes; outcome assessor yes.<BR/>Intention to treat: No<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Texas, USA<BR/>Setting: Secondary care outpatient<BR/>Inclusion criteria: FPG &gt;7.77 mmol/l with max. Dose of sulphonylurea, FPG&lt; 15.54 mmol/l without sulphonylurea. <BR/>Exclusion criteria: Other medication known to affect glucose metabolism, prior insulin treatment , regular vigorous exercise, other major illness other than diabetes.<BR/>Patients randomised: 30<BR/>Nr of patients/group: 10 / 10 / 10<BR/>Drop-outs / loss to follow-up: 1 / 1 / 0<BR/>Nr of patients/group analysed: 9 / 9 / 10<BR/>Age (years, mean): 53 yrs (all subjects)<BR/>Sex (% male): not given<BR/>Diabetes duration (years): not stated<BR/>Diabetes therapy: Glipizide 20 mg bd (2-month run-in period)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Glipizide 20 mg bd + bedtime NPH insulin (Novolin-N, Novo Nordisk)<BR/>Group 2: Placebo + bedtime NPH insulin<BR/>Group 3: Glipizide 20 mg bd<BR/>Glucose targets to which insulin doses were titrated: first 3 months, insulin given as 5 units / 1.73 m2 and titrated to 20 units / 1.73 m2 (low-dose) <BR/>Second 3 months, target FPG 3.89-6.66 mmol/l<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: HbA1c (microcollumn affinity chromatography, normal range 3.1-6.1%), FPG<BR/>Weight: Weight gain<BR/>Insulin amount (E): Mean daily insulin dose at final visit<BR/>Hypoglycaemia: Symptomatic (and asymptomatic &lt;3.89 mmol/l) hypoglycaemic episodes<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: not reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 6 (no ITT)<BR/>Sponsoring: Support by grants from roerig-Pfizer, Novo Nordisk, Geriatric research and clinical centre, Veterens Affairs Medical Research Service.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sun-1995">
<CHAR_METHODS>
<P>Design: Randomised placebo controlled trial<BR/>Duration: 4 months<BR/>Randomisation procedure: not stated<BR/>Blinding: patients yes; care provider unclear; outcome assessor unclear.<BR/>Intention to treat: yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: China<BR/>Setting: Secondary care outpatient <BR/>Inclusion criteria: Age &gt;40 yrs, type 2 diabetes &gt;5 yrs duration, treatment with max. Sulphonylurea &gt; 3 weeks, FBG &gt; 7.8 mmol/l, 2hr post-prandial &gt; 11.1 mmol/l. <BR/>Exclusion criteria: not stated<BR/>Patients randomised: 33<BR/>Nr of patients/group: 12 / 11 / 10<BR/>Drop-outs / loss to follow-up: 0 / 0 / 0<BR/>Nr of patients/group analysed: 12 / 11 / 10<BR/>Age (years, mean): 53.6 / 54.4 /54.5 yrs<BR/>Sex (% male): 50% / 45% / 60% male<BR/>Diabetes duration (years): not stated<BR/>Diabetes therapy: Gliquidone 60 mg tds, 3 weeks run-in</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Gliquidone 60 mg tds + bedtime NPH (0.4 units/kg, Novo Nordisk)<BR/>Group 2: Placebo + NPH (0.4 units/kg) <BR/>Group 3: Gliquidone 60 mg tds<BR/>Glucose targets to which insulin doses were titrated: not stated<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: HbA1c (method not given, normal range &lt; 6%), FBG<BR/>Weight: not reported<BR/>Insulin amount (E): not given<BR/>Hypoglycaemia: Symptomatic hypoglycaemic episodes<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: not reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 3<BR/>Sponsoring: Supported by Novo Nordisk and Boehringer Ingelheim.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wolffenbuttel-1991">
<CHAR_METHODS>
<P>Design: randomised controlled trial<BR/>Duration: 6 months<BR/>Randomisation procedure: &#8220;aselect assignment&#8221; <BR/>Blinding: patients no; care provider no; outcome assessor no<BR/>Intention to treat: unclear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Netherlands<BR/>Setting: secondary care outpatient<BR/>Inclusion criteria: FBG &gt; 8.0 mmol/l; maximal dosage SU (glibenclamide) and/or metformin <BR/>Exclusion criteria: unclear <BR/>Patients randomised: 47<BR/>Nr of patients/group: 22 / 25<BR/>Drop-outs / loss to follow-up: 0 / 0 <BR/>Nr of patients/group analysed: 22 / 25<BR/>Age (years): 70 / 68<BR/>Sex (% male): 83 / 47<BR/>Diabetes duration (median; years): 9 / 10 <BR/>Diabetes therapy: glibenclamide 15 mg (27 patients); glibenclamide 15 mg + metformin (dose not reported) (20 patients) <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: intermediate-acting insulin (NPH) before breakfast and dinner; eventually replaced by mixed insulin (30% short-acting and 70% intermediate-acting) in case of post-prandial BG &gt; 10.0 mmol/l<BR/>Group 2: intermediate-acting insulin (NPH) before breakfast or bedtime + glibenclamide 15 mg; eventually a second injection was added in case of post-prandial BG &gt; 10.0 mmol/l<BR/>Glucose targets to which insulin doses were titrated: FBG &lt; 7.0 mmol/l; post-prandial BG &lt; 10.0 mmol/l; HbA1c &lt; 8.0%<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: FBG; HbA1c<BR/>Weight: weight<BR/>Insulin amount (E): daily dose<BR/>Hypoglycaemia: reported qualitatively <BR/>Well-being: reported qualitatively<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: not reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 0<BR/>Sponsoring: Novo Nordisk Pharmaceuticals, Diabetes Research Fund</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wolffenbuttel-1996">
<CHAR_METHODS>
<P>Design: Randomised controlled trial<BR/>Duration: 6 months<BR/>Randomisation procedure: not stated<BR/>Blinding: patients no; care provider no; outcome assessor no.<BR/>Intention to treat: no<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Netherlands<BR/>Setting: Secondary care outpatient<BR/>Inclusion criteria: Fasting blood glucose (mean of 3 measurements) &gt;8.0 mmol/l, HbA1c &gt; 8.9% despite diet &amp; max. oral hypoglycaemic agents (glibenclamide 15 mg / day ±metformin). <BR/>Exclusion criteria: Intercurrent illness, cardiac, hepatic, renal or other endocrine disease. Severe untreated hypertension (diastolic BP &gt; 110 mm Hg), impaired renal function (creatinine &gt; 140 micromol/l), or treatment with corticosteroids.<BR/>Patients randomised: 102<BR/>Nr of patients/group: 34 / 28 / 33 <BR/>Drop-outs / loss to follow-up: 7 (unclear which group(s))<BR/>Nr of patients/group analysed: 34 / 28 / 33<BR/>Age (years, mean): 68 yrs (completers)<BR/>Sex (% male): 39% male (completers)<BR/>Diabetes duration (years): median 9 yrs (completers) <BR/>Diabetes therapy: Glibenclamide 15 mg/day (n=66), Glibenclamide 15 mg/day + metformin (n=29)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Twice-daily insulin mixture (Mixtard 30/70, 30% short acting, 70% NPH, Novo Nordisk)<BR/>Group 2: Glibenclamide 10 mg +5mg + bedtime NPH insulin<BR/>Group 3: Glibenclamide 10 mg +5mg + NPH insulin before breakfast<BR/>Glucose targets to which insulin doses were titrated:<BR/>Fasting blood glucose &lt; 7.0 mmol/l, pre-prandial glucose &lt; 10 mmol/l, HbA1c &lt;8.0%.<BR/>If daytime/evening (group 2) or bedtime (group 3) blood glucose exceeded 10 mmol/l, subjects were switched to a regimen consisting of NPH insulin before breakfast and at bedtime with continued glibenclamide<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: HbA1c (HPLC assay, normal range 4.4-6.2%), FBG<BR/>Weight: Weight gain<BR/>Insulin amount (E): Mean daily insulin dose at final visit<BR/>Hypoglycaemia: Severe hypoglycaemic episodes reported<BR/>Well-being: not formally reported<BR/>Treatment Satisfaction: not formally reported<BR/>Adverse events: Reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 1 ? ( withdrawals &amp; dropouts described?)<BR/>Sponsoring: Supported by Novo Nordisk and Boehringer Ingelheim.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Xu-2001">
<CHAR_METHODS>
<P>Design: Randomised controlled trial<BR/>Duration: 6 months<BR/>Randomisation procedure: unclear<BR/>Blinding: unclear<BR/>Intention to treat: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: China<BR/>Setting: Sec care outpat and sec inpat<BR/>Inclusion criteria: data missing <BR/>Exclusion criteria: data missing <BR/>Patients randomised: 90<BR/>Nr of patients/group: 45 / 45<BR/>Drop-outs / loss to follow-up: 0 / 0 <BR/>Nr of patients/group analysed: 45 / 45<BR/>Age (years, mean): 51.4 / 52.1<BR/>Sex (% male): 47 / 51<BR/>Diabetes duration (years;(SD)): 7.3 (4.5) / 7.4 (4.8) <BR/>Diabetes therapy: OHAs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: insulin once daily 24 IU/day <BR/>Group 2: metformin 1500 daily + insulin once daily 24U/day <BR/>Glucose targets to which insulin doses were titrated: 3.5 - 7.0 mmol/l</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: HbA1c (method and normal range not given), FBG<BR/>Weight: data missing<BR/>Insulin amount (IU): fixed insulin dose in both groups <BR/>Hypoglycaemia: not reported<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: not reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 0<BR/>Sponsoring: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1992">
<CHAR_METHODS>
<P>Design: Randomised controlled trial<BR/>Duration: 3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Finland<BR/>Setting: Secondary care outpatient<BR/>Inclusion criteria: Age 40-70 yrs, type 2 diabetes &gt; 3 yrs, BMI &lt;35 kg/m2, FPG &gt; 8.0 mmol/l despite max. sulphonylurea ±metformin. Fasting C-peptide &gt; 0.33 mol/l.<BR/>Exclusion criteria: Congestive cardiac failure, myocardial infarction or stroke within 6 months; epilepsy or other severe disease; liver disease; nephropathy (serum creatinine &gt; 120 micromol/l or albuminuria &gt; 300 mg/24 hrs; proliferative diabetic retinopathy or severe maculopathy; previous insulin therapy for more than 2 weeks; excess alcohol consumption; night shift work; serum triglycerides &gt; 5mmol/l; presence of islet cell antibodies.<BR/>Patients randomised: 153<BR/>Nr of patients/group: 32 / 28 / 30 / 31 / 32<BR/>Drop-outs / loss to follow-up: 0 / 0 / 1 / 1 / 2<BR/>Nr of patients/group analysed: 32 / 28 / 29 / 30 / 30<BR/>Age (years, mean): 59 / 60 / 59 / 60 / 59 yrs (completers)<BR/>Sex (% male): 38 / 54 / 41 / 60 / 37% (completers)<BR/>Diabetes duration (years): 11 / 10 / 10 / 11 / 10 (completers) <BR/>Diabetes therapy: Glibenclamide (mg/day) 11 / 11 / 12 / 11 / 11 Glipizide (mg/day) 18 / 19 / 17 / 22 / 18 Metformin (g/day) 1.3 / 1.3 / 1.2 / 1.4 / 1.4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Oral hypoglycaemic agent therapy (unchanged: SU +/- metformin) + NPH insulin before breakfast (Novo Nordisk)Group 2: Oral hypoglycaemic agent therapy (unchanged) + 9 pm NPH insulin Group 3: NPH and regular insulin (70:30) before breakfast and dinner Group 4: Basal-bolus regimen (actrapid soluble insulin before meals, 9pm NPH)Group 5: Oral hypoglycaemic agent therapy (unchanged) (control group)(add groups if appropriate) Glucose targets to which insulin doses were titrated:FBG &lt; 7.0 mmol/l, post-prandial &lt;10 mmol/lInsulin starting doses Groups 1 &amp; 2: Insulin dose equalled mean diurnal blood glucose concentration (mmol/l)Group 3: 0.25 units/kg + 4 units for each mmol/l mean diurnal blood glucose concentration exceeded 10 mmol/l. Two thirds given at 7am, one third at 4pm.Group 4: As for group 3. Two thirds given at before meals, one third at 9pm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: HbA1c (HPLC assay, 4-6%), FBG<BR/>Weight: Weight gain<BR/>Insulin amount (E): Mean daily insulin dose at final visit<BR/>Hypoglycaemia: Symptomatic and biochemical (&lt;4.0 mmol/l) hypoglycaemia<BR/>Well-being: Reported though method not stated<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: Those resulting in withdrawal reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 4<BR/>Sponsoring: Supported by grants from Novo Nordisk, Finnish State Medical Research Council, Sigrid Juselius research foundation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1999">
<CHAR_METHODS>
<P>Design: Randomised placebo controlled trial<BR/>Duration: 1 year<BR/>Randomisation procedure: &#8220;minimization of differences&#8221;<BR/>Blinding: patients yes; care provider no; outcome assessor no.<BR/>Intention to treat: no<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Finland<BR/>Setting: Secondary care outpatient<BR/>Inclusion criteria: Age 40-70 yrs, BMI &lt;35 kg/m2, FBG &gt;8.0 mmol/l, diabetes duration &gt;3 yrs, previous oral therapy with max. SU (glipizide &gt;15 mg / day, glibenclamide &gt;10 mg / day. Fasting C-peptide &gt;0.33nmol/l.<BR/>Exclusion criteria: NYHA grade III/IV heart failure, MI or stroke within 6 months, epilepsy or other severe disease, liver disease unrelated to diabetes, nephropathy (macroalbuminuria or serum creatinine &gt;120 micromol/l, proliferative retinopathy or severe maculopathy, insulin theraspy for more than 2 weeks, excessive alcohol consumption, night shift work.<BR/>Patients randomised: 96<BR/>Nr of patients/group: 24 / 24 / 24 / 24<BR/>Drop-outs / loss to follow-up: 2 / 5 / 1 / 0<BR/>Nr of patients/group analysed: 22 / 19 / 23 / 24<BR/>Age (years, mean): 61 / 57 / 55 / 58 yrs (completers)<BR/>Sex (% male): 59 / 58 / 61 / 67 % (completers) <BR/>Diabetes duration (years): not stated <BR/>Diabetes therapy: glipizide &gt;15mg / day, glibenclamide &gt;10 mg / day</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Glibenclamide 3.5mg + 7mg + bedtime NPH insulin (+ metformin placebo)<BR/>Group 2: Metformin 1g bd + bedtime NPH insulin (+ glibenclamide placebo)<BR/>Group 3: Glibenclamide (3.5mg + 7mg) + metformin (1g bd) + bedtime NPH insulin<BR/>Group 4: BD NPH insulin</P>
<P>Glucose targets to which insulin doses were titrated:<BR/>FPG &lt;6.0mmol/l<BR/>Starting dose of NPH = FPG (mmol/l), FPG measured daily. Insulin increased by 4 units if 3 successive FPG readings &gt; 8 mmol/l, and 2 units if &gt; 6.0 mmol/l</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glycaemia: HbA1c (HPLC method, normal range not given), FPG<BR/>Weight: Weight gain, BMI<BR/>Insulin amount (E): Mean daily insulin dose at final visit <BR/>Hypoglycaemia: not reported<BR/>Well-being: not reported<BR/>Treatment Satisfaction: not reported<BR/>Adverse events: Reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 4<BR/>Sponsoring: Supported by grant from the Acadamy of Finland<BR/>Structured patient-led insulin titration regimen<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Abbreviations: BMI = body mass index, CCF = congestive cardiac failure, CPG = capillary blood glucose, (F)BG = (fasting) blood glucose, FPG = fasting plasma glucose, HPLC = high performance liquid chromatography, IBW = ideal bodyweight, MI = myocardial infarction, NPH = neutral protamine hegedorn, OHA = oral hypoglycaemic agents, PVD = peripheral vascular disease, SU = sulphonylurea</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Allen-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aviles-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bastyr-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bieger-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Birkeland-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Birkeland-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bruns-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a RCT; follow-up &lt; 2 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Calle-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Camerini-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated (62% of patients)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carta-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Casner-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>previous insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Castillo-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chazan-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chiasson-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Clauson-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cortes-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>patients well-controlled at inclusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Diehl-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elgrably-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Falko-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Feinglos-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Feinglos-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Firth-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin /oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Firth-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin /oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fonseca-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fritsche-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Giugliano-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Groop-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Groop-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Groop-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Groop-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin /oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Groop-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guvener-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hamelbeck-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>follow-up&lt; 2 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hirsch-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Josse-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kasim-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kelley-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kitabchi-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klein-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kyllastinen-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Landstedt-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Landstedt-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lardinois-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lawrence-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lebovitz-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lewitt-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Liedtke-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>follow-up &lt; 2 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lindstrom-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin /oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lindstrom-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lins-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Longnecker-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lopez-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin /oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martin-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mauerhoff-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mezitis-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>previous insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mohan-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nathan-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>patients on diet alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Niazi-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Niskanen-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Okada-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Osei-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Panahloo-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>patients on diet alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pasmantier-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>study on human pro-insulin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peacock-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Polo-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>study on combination nicotinamide with insulin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ponssen-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Quatraro-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Raskin-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reich-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Relimpio-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rivellese-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robinson-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rodier-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Romano-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosak-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Samanta-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>newly diagnosed type 2 diabetes patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sanchez-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sane-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sangiorgio-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schade-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schwartz-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schwartz-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simonson-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simpson-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sinagra-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Soneru-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sotaniemi-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>follow-up &lt; 2 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Standl-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stenman-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stocks-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stradner-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thompson-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tovi-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Trischitta-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Trischitta-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Trznadel-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Turner-1999-_x0028_2_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-UKPDS-13-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-UKPDS-24-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-UKPDS-33-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vigneri-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolffenbuttel-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin / oha combination therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yki_x002d_Jarvinen-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>no insulin monotherapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yu-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yudkin-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Goudswaard-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Olsson-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Stehouwer-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bachmann-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Bastyr-1999">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Chow-1995">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-F_x00f6_v_x00e9_nyi-1997">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gutniak-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Holman-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karlander-1991">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Lotz-1988">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lundershausen-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-M_x00e4_kimattila-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pontiroli-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ravnik_x002d_Oblak-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Riddle-1989">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Riddle-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Riddle-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shank-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sun-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wolffenbuttel-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wolffenbuttel-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Xu-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-10-03 17:15:10 +0200" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-10-28 13:04:26 +0100" MODIFIED_BY="Gudrun Paletta">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Insulin once daily versus insulin once daily plus oral antihyperglycaemic agents (OHAs)</NAME>
<CONT_OUTCOME CHI2="4.7802928663238875" CI_END="0.6171064055889751" CI_START="0.03491298647431462" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.32600969603164487" ESTIMABLE="YES" I2="16.32311843947636" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.3105928093065715" P_Q="1.0" P_Z="0.028161137209414787" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.019280265416690073" TOTALS="YES" TOTAL_1="148" TOTAL_2="149" UNITS="" WEIGHT="100.0" Z="2.195034302533168">
<NAME>HbA1c (change from baseline [%])</NAME>
<GROUP_LABEL_1>insulin</GROUP_LABEL_1>
<GROUP_LABEL_2>insulin-OHA</GROUP_LABEL_2>
<GRAPH_LABEL_1>insulin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>insulin-OHA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.7802928663238875" CI_END="0.6171064055889751" CI_START="0.03491298647431462" DF="4.0" EFFECT_SIZE="0.32600969603164487" ESTIMABLE="YES" I2="16.32311843947636" ID="CMP-001.01.01" NO="1" P_CHI2="0.3105928093065715" P_Z="0.028161137209414787" STUDIES="5" TAU2="0.019280265416690073" TOTAL_1="148" TOTAL_2="149" WEIGHT="100.0" Z="2.195034302533168">
<NAME>insulin once daily versus insulin nph bedtime plus sulphonylurea (SU)</NAME>
<CONT_DATA CI_END="5.933486828273324" CI_START="-0.9334868282733235" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-5.5" ORDER="6" SD_1="3.53" SD_2="4.82" SE="1.751811183958598" STUDY_ID="STD-Sun-1995" TOTAL_1="11" TOTAL_2="12" WEIGHT="0.7143052866285163"/>
<CONT_DATA CI_END="0.4255400410134141" CI_START="-0.2255400410134139" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-2.2" ORDER="6" SD_1="1.0" SD_2="1.0" SE="0.16609490969284757" STUDY_ID="STD-Riddle-1998" TOTAL_1="73" TOTAL_2="72" WEIGHT="47.065641980242994"/>
<CONT_DATA CI_END="0.9364607003135812" CI_START="0.0635392996864188" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-1.3" ORDER="7" SD_1="0.63" SD_2="0.33" SE="0.22268812271874763" STUDY_ID="STD-Riddle-1992" TOTAL_1="10" TOTAL_2="11" WEIGHT="32.02924149681596"/>
<CONT_DATA CI_END="2.7928462069065274" CI_START="-0.5928462069065275" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-1.8" ORDER="16861" SD_1="1.74" SD_2="1.92" SE="0.8637129152675673" STUDY_ID="STD-Shank-1995" TOTAL_1="9" TOTAL_2="9" WEIGHT="2.8824242080512836"/>
<CONT_DATA CI_END="1.044600076944295" CI_START="-0.24460007694429498" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-1.7" ORDER="16863" SD_1="1.55" SD_2="1.57" SE="0.3288836335916466" STUDY_ID="STD-Xu-2001" TOTAL_1="45" TOTAL_2="45" WEIGHT="17.308387028261247"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-10-28 13:04:26 +0100" MODIFIED_BY="Gudrun Paletta" NO="2">
<NAME>insulin twice daily versus insulin plus OHAs</NAME>
<CONT_OUTCOME CHI2="46.44071965383338" CI_END="0.2824963510646761" CI_START="-0.6708381047319623" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.19417087683364312" ESTIMABLE="YES" I2="80.62045535235993" I2_Q="90.48255928814818" ID="CMP-002.01" MODIFIED="2008-10-28 13:04:16 +0100" MODIFIED_BY="Gudrun Paletta" NO="1" P_CHI2="4.987439996551046E-7" P_Q="2.7343818310265888E-5" P_Z="0.42464229199629655" Q="21.014052627713802" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.4354475773231902" TOTALS="SUB" TOTAL_1="375" TOTAL_2="364" UNITS="" WEIGHT="300.0" Z="0.7983933091403644">
<NAME>HbA1c (change from baseline [%])</NAME>
<GROUP_LABEL_1>insulin</GROUP_LABEL_1>
<GROUP_LABEL_2>insulin-OHA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin-OHA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="20.93400658801506" CI_END="1.0922888969181377" CI_START="-0.9296177378721989" DF="2.0" EFFECT_SIZE="0.08133557952296941" ESTIMABLE="YES" I2="90.44616714153027" ID="CMP-002.01.01" NO="1" P_CHI2="2.8460372254679456E-5" P_Z="0.874702968790851" STUDIES="3" TAU2="0.7036833498427053" TOTAL_1="203" TOTAL_2="188" WEIGHT="100.00000000000001" Z="0.1576876041491839">
<NAME>insulin twice daily versus insulin nph bedtime plus sulphonylurea (SU)</NAME>
<CONT_DATA CI_END="9.624351291256383E-4" CI_START="-1.1609624351291257" EFFECT_SIZE="-0.5800000000000001" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-2.32" ORDER="1" SD_1="1.21" SD_2="1.12" SE="0.2964148523705962" STUDY_ID="STD-Wolffenbuttel-1996" TOTAL_1="34" TOTAL_2="28" WEIGHT="33.54942978495781"/>
<CONT_DATA CI_END="1.0956631133827077" CI_START="0.5643368866172925" EFFECT_SIZE="0.8300000000000001" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-2.23" ORDER="1" SD_1="1.11" SD_2="1.18" SE="0.1355448954563575" STUDY_ID="STD-F_x00f6_v_x00e9_nyi-1997" TOTAL_1="145" TOTAL_2="141" WEIGHT="38.686550131493206"/>
<CONT_DATA CI_END="0.7697203970823914" CI_START="-0.9697203970823915" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.9" ORDER="4" SD_1="1.5" SD_2="1.4" SE="0.4437430503532896" STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1999" TOTAL_1="24" TOTAL_2="19" WEIGHT="27.764020083549"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.9898371796340397" CI_END="0.3795959726376168" CI_START="-0.7235775204262482" DF="2.0" EFFECT_SIZE="-0.17199077389431572" ESTIMABLE="YES" I2="33.10672522157869" ID="CMP-002.01.02" MODIFIED="2008-10-28 13:04:16 +0100" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="0.22426692741804333" P_Z="0.5411081063478989" STUDIES="3" TAU2="0.07885180095641796" TOTAL_1="79" TOTAL_2="78" WEIGHT="100.0" Z="0.6111381838405274">
<NAME>insulin twice daily versus insulin nph bedtime plus sulphonylurea (SU) + metformin</NAME>
<CONT_DATA CI_END="0.05184178213817736" CI_START="-1.5718417821381778" EFFECT_SIZE="-0.7600000000000002" ESTIMABLE="YES" MEAN_1="-2.16" MEAN_2="-1.4" ORDER="1" SD_1="1.74" SD_2="1.22" SE="0.4142126021405913" STUDY_ID="STD-Chow-1995" TOTAL_1="26" TOTAL_2="27" WEIGHT="32.69402717164074"/>
<CONT_DATA CI_END="0.8107137173548463" CI_START="-0.6107137173548466" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-1.9" ORDER="4" SD_1="1.6" SD_2="1.1" SE="0.3626157026153876" STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1992" TOTAL_1="29" TOTAL_2="28" WEIGHT="35.00546230023195"/>
<CONT_DATA CI_END="0.9291537034487057" CI_START="-0.7291537034487056" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-2.1" ORDER="4" SD_1="1.5" SD_2="1.4" SE="0.42304537735844344" STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1999" TOTAL_1="24" TOTAL_2="23" WEIGHT="32.30051052812731"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5028232584704817" CI_END="-0.04979709002930316" CI_START="-0.8189982030146723" DF="3.0" EFFECT_SIZE="-0.4343976465219877" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.03" MODIFIED="2008-10-28 13:04:16 +0100" MODIFIED_BY="Gudrun Paletta" NO="3" P_CHI2="0.6816189068718604" P_Z="0.026847008540006503" STUDIES="4" TAU2="0.0" TOTAL_1="93" TOTAL_2="98" WEIGHT="99.99999999999999" Z="2.213735075987212">
<NAME>insulin twice daily versus insulin nph morning plus sulphonylurea (SU) or SU+metformin</NAME>
<CONT_DATA CI_END="0.18988656083210298" CI_START="-0.9498865608321028" EFFECT_SIZE="-0.3799999999999999" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-2.52" ORDER="1" SD_1="1.21" SD_2="1.17" SE="0.2907637922570493" STUDY_ID="STD-Wolffenbuttel-1996" TOTAL_1="34" TOTAL_2="33" WEIGHT="31.156990810297387"/>
<CONT_DATA CI_END="0.6629129142973462" CI_START="-2.602912914297346" EFFECT_SIZE="-0.97" ESTIMABLE="YES" MEAN_1="-1.72" MEAN_2="-0.75" ORDER="1" SD_1="1.6" SD_2="1.73" SE="0.8331341428605601" STUDY_ID="STD-Lotz-1988" TOTAL_1="8" TOTAL_2="8" WEIGHT="14.343070479721865"/>
<CONT_DATA CI_END="0.72827521920141" CI_START="-0.9282752192014102" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-1.7" ORDER="4" SD_1="1.6" SD_2="1.7" SE="0.4225971628737769" STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1992" TOTAL_1="29" TOTAL_2="32" WEIGHT="26.385035078182216"/>
<CONT_DATA CI_END="0.05546362026287999" CI_START="-1.4154636202628803" EFFECT_SIZE="-0.6800000000000002" ESTIMABLE="YES" MEAN_1="-3.1" MEAN_2="-2.42" ORDER="16871" SD_1="1.26" SD_2="1.31" SE="0.375243436136645" STUDY_ID="STD-Wolffenbuttel-1991" TOTAL_1="22" TOTAL_2="25" WEIGHT="28.11490363179853"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.709430826173405" CI_END="1.958633776910848" CI_START="-0.07947426454587747" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.9395797561824852" ESTIMABLE="YES" I2="58.802940444074984" I2_Q="79.41926406714336" ID="CMP-002.02" MODIFIED="2008-10-28 13:04:26 +0100" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="0.045617360351765224" P_Q="0.027503784569206657" P_Z="0.07074516475057842" Q="4.858912738895427" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.7051006430941462" TOTALS="SUB" TOTAL_1="248" TOTAL_2="241" UNITS="" WEIGHT="200.0" Z="1.8071097755979266">
<NAME>weight gain (change from baseline[kg]]</NAME>
<GROUP_LABEL_1>insulin</GROUP_LABEL_1>
<GROUP_LABEL_2>insulin-OHA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin-OHA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.1632676659787115" CI_END="0.5782313886274207" CI_START="-0.15484414395674817" DF="1.0" EFFECT_SIZE="0.21169362233533628" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" NO="1" P_CHI2="0.6861659293176263" P_Z="0.2576446339376848" STUDIES="2" TAU2="0.0" TOTAL_1="169" TOTAL_2="163" WEIGHT="100.0" Z="1.1319757844637777">
<NAME>insulin twice daily versus insulin nph bedtime plus sulphonylurea (SU)</NAME>
<CONT_DATA CI_END="0.5709005973652765" CI_START="-0.17090059736527624" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="2.5" ORDER="16874" SD_1="1.6" SD_2="1.6" SE="0.18923847595715687" STUDY_ID="STD-F_x00f6_v_x00e9_nyi-1997" TOTAL_1="145" TOTAL_2="141" WEIGHT="74.81116133766207"/>
<CONT_DATA CI_END="3.096785669345441" CI_START="-1.6967856693454415" EFFECT_SIZE="0.6999999999999997" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="3.9" ORDER="16875" SD_1="4.9" SD_2="3.3" SE="1.222872301864208" STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1999" TOTAL_1="24" TOTAL_2="22" WEIGHT="25.18883866233793"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.687250421299266" CI_END="3.182055184363561" CI_START="-0.09606861214327234" DF="2.0" EFFECT_SIZE="1.5429932861101443" ESTIMABLE="YES" I2="57.33106149157662" ID="CMP-002.02.02" MODIFIED="2008-10-28 13:04:26 +0100" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="0.09597925884181602" P_Z="0.0650249311361518" STUDIES="3" TAU2="1.1938385128820663" TOTAL_1="79" TOTAL_2="78" WEIGHT="100.0" Z="1.8450866757293232">
<NAME>insulin twice daily versus insulin nph bedtime plus sulphonylurea (SU) + metformin</NAME>
<CONT_DATA CI_END="4.936539532615433" CI_START="1.2634604673845669" EFFECT_SIZE="3.1" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="2.1" ORDER="16876" SD_1="4.1" SD_2="2.5" SE="0.9370271837145083" STUDY_ID="STD-Chow-1995" TOTAL_1="26" TOTAL_2="27" WEIGHT="33.33280178640736"/>
<CONT_DATA CI_END="1.9759001360367736" CI_START="-0.7759001360367734" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.2" ORDER="16877" SD_1="2.7" SD_2="2.6" SE="0.7020027647904238" STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1992" TOTAL_1="29" TOTAL_2="28" WEIGHT="44.05164802275435"/>
<CONT_DATA CI_END="3.5009653112622514" CI_START="-1.5009653112622523" EFFECT_SIZE="0.9999999999999996" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="3.6" ORDER="16878" SD_1="4.9" SD_2="3.8" SE="1.2760261571077565" STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1999" TOTAL_1="24" TOTAL_2="23" WEIGHT="22.615550190838288"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>insulin basal/bolus versus insulin plus OHA</NAME>
<CONT_OUTCOME CHI2="0.41883083600951243" CI_END="0.13703983297067743" CI_START="-0.4443908068781778" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1536754869537502" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.5175210287892659" P_Q="1.0" P_Z="0.30017431835722097" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="179" TOTAL_2="167" UNITS="" WEIGHT="100.0" Z="1.0360596745101112">
<NAME>HbA1c (change from baseline [%])</NAME>
<GROUP_LABEL_1>insulin</GROUP_LABEL_1>
<GROUP_LABEL_2>insulin-OHA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin-OHA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.41883083600951243" CI_END="0.13703983297067743" CI_START="-0.4443908068781778" DF="1.0" EFFECT_SIZE="-0.1536754869537502" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="0.5175210287892659" P_Z="0.30017431835722097" STUDIES="2" TAU2="0.0" TOTAL_1="179" TOTAL_2="167" WEIGHT="100.0" Z="1.0360596745101112">
<NAME>insulin basal/bolus versus insulin nph bedtime plus sulphonylurea (SU) +/- metformin</NAME>
<CONT_DATA CI_END="0.12083339085458311" CI_START="-0.500833390854583" EFFECT_SIZE="-0.18999999999999995" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-1.21" ORDER="4" SD_1="1.46" SD_2="1.21" SE="0.15859137887552893" STUDY_ID="STD-Bastyr-1999" TOTAL_1="149" TOTAL_2="135" WEIGHT="87.47430584612077"/>
<CONT_DATA CI_END="0.9214232987787134" CI_START="-0.7214232987787137" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-1.7" ORDER="6" SD_1="1.6" SD_2="1.7" SE="0.4191012208683403" STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1992" TOTAL_1="30" TOTAL_2="32" WEIGHT="12.525694153879233"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9129725044941164" CI_END="1.6567202236202265" CI_START="0.5315812391040204" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0941507313621235" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="0.33932708713381354" P_Q="1.0" P_Z="1.378655960723928E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="179" TOTAL_2="163" UNITS="" WEIGHT="100.00000000000001" Z="3.811966444394468">
<NAME>weight gain (change from baseline[kg]]</NAME>
<GROUP_LABEL_1>insulin</GROUP_LABEL_1>
<GROUP_LABEL_2>insulin-OHA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin-OHA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9129725044941164" CI_END="1.6567202236202265" CI_START="0.5315812391040204" DF="1.0" EFFECT_SIZE="1.0941507313621235" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" NO="1" P_CHI2="0.33932708713381354" P_Z="1.378655960723928E-4" STUDIES="2" TAU2="0.0" TOTAL_1="179" TOTAL_2="163" WEIGHT="100.00000000000001" Z="3.811966444394468">
<NAME>insulin basal/bolus versus insulin nph bedtime plus sulphonylurea (SU) +/- metformin</NAME>
<CONT_DATA CI_END="1.5875260930472965" CI_START="0.35247390695270375" EFFECT_SIZE="0.9700000000000001" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="0.57" ORDER="16881" SD_1="3.05" SD_2="2.23" SE="0.31507012267483653" STUDY_ID="STD-Bastyr-1999" TOTAL_1="149" TOTAL_2="135" WEIGHT="82.99305049833929"/>
<CONT_DATA CI_END="3.0641526339492" CI_START="0.3358473660507999" EFFECT_SIZE="1.7" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="1.2" ORDER="16882" SD_1="2.7" SD_2="2.6" SE="0.6960090311400934" STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1992" TOTAL_1="30" TOTAL_2="28" WEIGHT="17.006949501660728"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Insulin monotherapy versus insulin plus metformine +/- sulphonylurea (SU)</NAME>
<CONT_OUTCOME CHI2="4.306604260365381" CI_END="0.6207067493928773" CI_START="-0.7768319596476909" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.07806260512740681" ESTIMABLE="YES" I2="53.5596985679312" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="0.11610021782290625" P_Q="1.0" P_Z="0.826684153913433" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.2039476643910468" TOTALS="YES" TOTAL_1="79" TOTAL_2="74" UNITS="" WEIGHT="100.0" Z="0.21895621724013056">
<NAME>HbA1c (change from baseline [%])</NAME>
<GROUP_LABEL_1>insulin</GROUP_LABEL_1>
<GROUP_LABEL_2>insulin-OHA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin-OHA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.05184178213817736" CI_START="-1.5718417821381778" EFFECT_SIZE="-0.7600000000000002" ESTIMABLE="YES" MEAN_1="-2.16" MEAN_2="-1.4" ORDER="1" SD_1="1.74" SD_2="1.22" SE="0.4142126021405913" STUDY_ID="STD-Chow-1995" TOTAL_1="26" TOTAL_2="27" WEIGHT="33.84844655350958"/>
<CONT_DATA CI_END="1.47182450538766" CI_START="-0.4718245053876601" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-2.5" ORDER="4" SD_1="1.5" SD_2="1.7" SE="0.49583794041793" STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1999" TOTAL_1="24" TOTAL_2="19" WEIGHT="28.258508808193938"/>
<CONT_DATA CI_END="0.8107137173548463" CI_START="-0.6107137173548466" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-1.9" ORDER="4" SD_1="1.6" SD_2="1.1" SE="0.3626157026153876" STUDY_ID="STD-Yki_x002d_J_x00e4_rvinen-1992" TOTAL_1="29" TOTAL_2="28" WEIGHT="37.89304463829647"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot for the outcome HbA1c</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-10-03 17:15:16 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-10-03 17:15:16 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-10-03 17:01:10 +0200" MODIFIED_BY="[Empty name]">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-03 17:15:16 +0200" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>Unless otherwise stated, search terms are free text terms; MeSH = Medical subject heading (Medline medical index term); exp = exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) = to substitute for one or no characters; tw = text word; pt = publication type; sh = MeSH; adj = adjacent.</P>
<P>1. exp Drug Combinations/<BR/>2. (drug therap$ or drug combination$).tw.<BR/>3. ((combination$ or oral or multiple) adj (therap$ or agent$ or drug$ or treatment$)).tw.<BR/>4. monotherap$.tw.<BR/>5. or/1-4<BR/>6. exp SULFONYLUREA COMPOUNDS/<BR/>7. exp BIGUANIDES/<BR/>8. exp ACARBOSE/<BR/>9. (biguanid$ or sulfonylurea$ or sulphonylurea$ or acarbose).tw.<BR/>10. (gliglacid$ or glibornurid$ or gliguidon$ or glisoxepid$ or glipizid$ or gliburid$ or<BR/>11. glyburid$ or tolazamid$).tw.<BR/>12. (tolbutamid$ or carbutamid$ or chlorpropamid$ or acetohexamid$ or glibenclamid$ or<BR/>13. glimepirid$).tw.<BR/>14. (metformin$ or buformin$ or chlorhexidin$ or chlorguanid$ or phenformin$).tw.<BR/>15. (miglitol$ or nateglinid$ or glucobay).tw.<BR/>16. (troglitazon$ or rosiglitazon$ or pioglitazon$ or thioazolidinedion$ or glitazon$).tw.<BR/>17. repaglinid$.tw.<BR/>18. exp INSULIN/<BR/>19. insulin$.tw.<BR/>20. ((antidiabet$ or anti diabet$) adj (drug$ or herb$ or agent$ or compound$)).tw.<BR/>21. (hypoglyc?emic adj (drug$ or herb$ or agent$ or compound$)).tw.<BR/>22. or/6-21<BR/>23. 5 and 22<BR/>24. exp diabetes mellitus, non-insulin-dependent/<BR/>25. exp insulin resistance/<BR/>26. impaired glucose toleranc$.tw.<BR/>27. glucose intoleranc$.tw.<BR/>28. insulin$ resistanc$.tw.<BR/>29. exp obesity in diabetes/<BR/>30. (obes$ adj diabet$).tw.<BR/>31. (MODY or NIDDM).tw.<BR/>32. (non insulin$ depend$ or noninsulin$ depend$ or noninsulin?depend$ or non<BR/>33. insulin?depend$).tw.<BR/>34. ((typ$ 2 or typ$ II) adj diabet$).tw.<BR/>35. ((keto?resist$ or non?keto$) adj diabet$).tw.<BR/>36. ((adult$ or matur$ or late or slow or stabl$) adj diabet$).tw.<BR/>37. (insulin$ defic$ adj relativ$).tw.<BR/>38. pluri?metabolic$ syndrom$.tw.<BR/>39. or/24-38<BR/>40. exp diabetes insipidus/<BR/>41. diabet$ insipidus.tw.<BR/>42. 40 or 41<BR/>43. 39 not 42<BR/>44. randomized controlled trial.pt.<BR/>45. controlled clinical trial.pt.<BR/>46. randomized controlled trials.sh.<BR/>47. random allocation.sh.<BR/>48. double-blind method.sh.<BR/>49. single-blind method.sh.<BR/>50. or/44-49<BR/>51. limit 50 to animal<BR/>52. limit 50 to human<BR/>53. 51 not 50<BR/>54. 50 not 53<BR/>55. clinical trial.pt.<BR/>56. exp clinical trials/<BR/>57. (clinic$ adj25 trial$).tw.<BR/>58. ((singl$ or doubl$ or trebl$ or tripl$) adj (mask$ or blind$)).tw.<BR/>59. placebos.sh.<BR/>60. placebo$.tw.<BR/>61. random$.tw.<BR/>62. research design.sh.<BR/>63. (latin adj square).tw.<BR/>64. or/55-63<BR/>65. limit 64 to animal<BR/>66. limit 64 to human<BR/>67. 65 not 66<BR/>68. 64 not 67<BR/>69. comparative study.sh.<BR/>70. exp evaluation studies/<BR/>71. follow-up studies.sh.<BR/>72. prospective studies.sh.<BR/>73. cross-over studies.sh.<BR/>74. exp Intervention Studies/<BR/>75. or/69-74<BR/>76. limit 75 to animals<BR/>77. limit 75 to human<BR/>78. 76 not 77<BR/>79. 75 not 78<BR/>80. 54 or 68 or 79<BR/>81. 23 and 43 and 80</P>
<P/>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>